

10-Q false0001484612--12-31Q20001484612us-gaap:InterestRateFloorMemberom:SlrRevolverMember2024-01-012024-06-300001484612us-gaap:RetainedEarningsMember2024-01-012024-03-310001484612us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-06-300001484612srt:MinimumMemberom:SlrRevolverMember2022-11-030001484612us-gaap:RetainedEarningsMember2024-03-310001484612us-gaap:RestrictedStockUnitsRSUMember2022-02-012022-02-280001484612us-gaap:EmployeeStockMember2024-01-012024-06-300001484612om:UnrealizedLossesLessThan12MonthsMember2023-12-310001484612om:SlrTermLoanFacilityMemberom:TermCLoanMember2024-01-012024-06-300001484612us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001484612us-gaap:ProductMember2024-01-012024-06-300001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300001484612us-gaap:CommonStockMember2023-12-310001484612us-gaap:RetainedEarningsMember2024-06-300001484612us-gaap:RetainedEarningsMember2023-12-310001484612om:ServiceAndOtherRevenueMember2024-01-012024-06-300001484612srt:MinimumMemberom:TotalShareholderReturnMember2024-01-012024-06-300001484612om:SlrCreditFacilitiesMember2024-06-300001484612om:SlrRevolverMemberus-gaap:AccountsReceivableMember2024-01-012024-06-300001484612us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001484612om:SlrTermLoanFacilityMemberom:FirstAnniversaryMember2024-01-012024-06-300001484612om:USGovernmentSponsoredEnterprisesMember2023-12-310001484612us-gaap:AdditionalPaidInCapitalMember2022-12-310001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001484612om:UnrealizedLosses12MonthsOrGreaterMember2023-12-310001484612us-gaap:FairValueMeasurementsRecurringMember2024-06-300001484612us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-06-300001484612om:TermALoanMemberom:SlrTermLoanFacilityMember2024-01-012024-06-300001484612us-gaap:CommonStockMember2024-04-012024-06-300001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001484612us-gaap:AdditionalPaidInCapitalMember2023-06-300001484612us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001484612us-gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300001484612us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-06-300001484612us-gaap:CorporateDebtSecuritiesMember2023-12-310001484612om:TotalShareholderReturnMembersrt:MaximumMember2024-01-012024-06-300001484612us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001484612us-gaap:CommonStockMember2023-03-3100014846122023-04-012023-06-300001484612us-gaap:CostOfSalesMember2024-01-012024-06-300001484612us-gaap:RetainedEarningsMember2023-03-310001484612us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310001484612us-gaap:CommonStockMember2024-01-012024-03-310001484612om:USGovernmentSponsoredEnterprisesMemberom:UnrealizedLossesLessThan12MonthsMember2023-12-310001484612om:StockOptionsToPurchaseCommonStockMember2024-01-012024-06-3000014846122023-01-012023-06-300001484612om:SecondAnniversaryMemberom:SlrTermLoanFacilityMember2024-01-012024-06-300001484612us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-06-300001484612us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300001484612us-gaap:CommonStockMember2022-12-310001484612us-gaap:USTreasurySecuritiesMember2023-12-310001484612srt:MinimumMember2024-01-012024-06-300001484612om:UnrealizedLossesLessThan12MonthsMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001484612om:UnrealizedLosses12MonthsOrGreaterMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300001484612us-gaap:SellingAndMarketingExpenseMember2023-01-012023-06-300001484612om:SlrTermLoanFacilityMember2024-01-012024-06-300001484612us-gaap:PerformanceSharesMember2024-01-012024-06-300001484612us-gaap:CommonStockMember2023-04-012023-06-300001484612om:SlrCreditFacilitiesMember2024-01-012024-06-300001484612us-gaap:EmployeeStockMember2023-01-012023-06-300001484612us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300001484612us-gaap:PerformanceSharesMembersrt:MaximumMember2024-01-012024-06-3000014846122022-04-012024-06-300001484612om:UnrealizedLossesLessThan12MonthsMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300001484612us-gaap:CommonStockMember2023-06-3000014846122024-07-310001484612us-gaap:USTreasurySecuritiesMemberom:UnrealizedLossesLessThan12MonthsMember2024-06-300001484612om:ConsumablesProductMember2024-04-012024-06-300001484612us-gaap:PerformanceSharesMembersrt:MinimumMember2024-01-012024-06-300001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310001484612us-gaap:ProductMember2023-04-012023-06-300001484612us-gaap:SellingAndMarketingExpenseMember2024-01-012024-06-300001484612om:TwoSeniorSecuredCreditFacilitiesMember2022-11-030001484612om:USGovernmentSponsoredEnterprisesMemberom:UnrealizedLossesLessThan12MonthsMember2024-06-300001484612om:ConsolesProductMember2024-01-012024-06-300001484612us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001484612om:TermALoanMemberom:SlrTermLoanFacilityMember2023-12-110001484612us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-3000014846122022-10-012024-06-3000014846122023-12-310001484612om:UnrealizedLossesLessThan12MonthsMember2024-06-3000014846122024-06-300001484612us-gaap:ProductMember2024-04-012024-06-300001484612om:SlrTermLoanFacilityMemberom:TermCLoanMember2023-12-110001484612us-gaap:CommercialPaperMember2024-06-300001484612us-gaap:PerformanceSharesMember2023-01-012023-06-300001484612us-gaap:PerformanceSharesMemberom:CeoMember2024-01-012024-06-300001484612om:SlrRevolverMember2024-01-012024-06-300001484612om:UnrealizedLosses12MonthsOrGreaterMemberus-gaap:CorporateDebtSecuritiesMember2023-12-

310001484612us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001484612om:StockOptionsToPurchaseCommonStockMember2023-01-012023-06-300001484612om:WarrantsToPurchaseCommonStockMember2024-01-012024-06-300001484612us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001484612us-gaap:OneTimeTerminationBenefitsMember2023-10-012023-12-310001484612om:SlrTermLoanFacilityMemberom:TermB2LoanMember2023-12-110001484612us-gaap:USTreasurySecuritiesMemberom:UnrealizedLossesLessThan12MonthsMember2023-12-310001484612om:EmployeesSharePurchasePlanMember2024-06-300001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001484612om:InitialRevolverCommitmentMemberom:SlrRevolverMember2024-01-012024-06-300001484612om:SlrTermLoanFacilityMember2023-12-110001484612us-gaap:PerformanceSharesMemberom:EndOfYear3Member2024-01-012024-06-300001484612us-gaap:SellingAndMarketingExpenseMember2023-04-012023-06-300001484612om:WarrantsToPurchaseCommonStockMember2024-04-012024-06-300001484612us-gaap:FairValueInputsLevel1Memberus-gaap:ShortTermInvestmentsMemberus-gaap:USTreasurySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001484612om:ServiceAndOtherRevenueMember2023-04-012023-06-300001484612us-gaap:CommercialPaperMemberom:UnrealizedLossesLessThan12MonthsMember2024-06-300001484612us-gaap:PerformanceSharesMember2023-04-012023-06-300001484612om:ServiceAndOtherRevenueMember2024-04-012024-06-300001484612us-gaap:CommercialPaperMemberom:UnrealizedLosses12MonthsOrGreaterMember2024-06-300001484612us-gaap:ProductMember2023-01-012023-06-300001484612srt:MaximumMember2024-01-012024-06-300001484612us-gaap:CommonStockMember2024-03-310001484612om:AdditionalTrancheMemberom:SlrRevolverMember2024-06-300001484612om:May2024WorkforceReductionPlanMemberus-gaap:OneTimeTerminationBenefitsMember2024-01-012024-03-310001484612us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001484612us-gaap:AdditionalPaidInCapitalMember2024-06-300001484612us-gaap:CommonStockMember2023-01-012023-03-310001484612om:ServiceAndOtherRevenueMember2023-01-012023-06-300001484612om:InitialRevolverCommitmentMemberom:SlrRevolverMember2024-06-300001484612om:ConsolesProductMember2023-04-012023-06-300001484612om:SlrTermLoanFacilityMemberom:TermB1LoanMember2023-12-110001484612us-gaap:PerformanceSharesMember2024-01-012024-06-300001484612us-gaap:FairValueAdjustmentToInventoryMemberom:SlrRevolverMember2024-01-012024-06-300001484612us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001484612us-gaap:RetainedEarningsMember2023-04-012023-06-300001484612om:SecondAnniversaryMemberom:SlrRevolverMember2024-01-012024-06-300001484612om:StockOptionsToPurchaseCommonStockMember2024-04-012024-06-300001484612us-gaap:FairValueMeasurementsRecurringMember2023-12-310001484612us-gaap:RestructuringChargesMember2024-01-012024-06-300001484612om:StockOptionsToPurchaseCommonStockMember2023-04-012023-06-300001484612om:SlrRevolverMemberom:AfterSecondAnniversaryMember2024-01-012024-06-300001484612us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-3000014846122024-01-012024-03-310001484612om:ConsumablesProductMember2023-04-012023-06-300001484612om:UnrealizedLosses12MonthsOrGreaterMemberus-gaap:USTreasurySecuritiesMember2023-12-3100014846122022-12-310001484612om:WarrantsToPurchaseCommonStockMember2023-04-012023-06-300001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001484612om:SlrTermLoanFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2024-01-012024-06-300001484612om:SlrRevolverMember2024-06-300001484612om:SlrTermLoanFacilityMemberom:TermBLoanMember2024-01-012024-06-300001484612us-gaap:EmployeeStockMember2023-04-012023-06-300001484612om:WarrantsToPurchaseCommonStockMember2023-01-012023-06-3000014846122024-04-012024-06-300001484612us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300001484612us-gaap:RetainedEarningsMember2023-01-012023-03-310001484612us-gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300001484612us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001484612om:USGovernmentSponsoredEnterprisesMember2024-06-300001484612us-gaap:PerformanceSharesMember2024-04-012024-06-300001484612us-gaap:SellingAndMarketingExpenseMember2024-04-012024-06-300001484612srt:ScenarioForecastMemberom:TheAugustTwoThousandTwentyFourRestructuringPlanMember2024-08-012024-08-310001484612us-gaap:AdditionalPaidInCapitalMember2024-03-310001484612om:SlrTermLoanFacilityMemberom:AfterSecondAnniversaryMember2024-01-012024-06-300001484612om:ConsolesProductMember2024-04-012024-06-300001484612om:ConsumablesProductMember2024-01-012024-06-3000014846122024-03-310001484612om:UnrealizedLosses12MonthsOrGreaterMemberom:USGovernmentSponsoredEnterprisesMember2024-06-300001484612om:ConsumablesProductMember2023-01-012023-06-300001484612us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-300001484612us-gaap:EmployeeStockMember2024-04-012024-06-300001484612om:UnrealizedLosses12MonthsOrGreaterMemberus-gaap:USTreasurySecuritiesMember2024-06-300001484612us-gaap:CorporateDebtSecuritiesMember2024-06-300001484612us-gaap:CommonStockMember2024-06-300001484612om:SlrRevolverMemberom:FirstAnniversaryMember2024-01-012024-06-300001484612us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001484612om:SlrCreditFacilitiesMembersrt:MaximumMember2022-11-030001484612us-gaap:RetainedEarningsMember2024-04-012024-06-300001484612us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001484612us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-

300001484612om:SlrTermLoanFacilityMemberom:TermBLoanMember2023-12-
110001484612om:CeoMemberom:TotalShareholderReturnMember2024-01-012024-06-
300001484612om:CeoMember2024-01-012024-06-300001484612us-
gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001484612us-
gaap:AdditionalPaidInCapitalMember2023-03-310001484612us-gaap:AdditionalPaidInCapitalMember2023-12-
310001484612us-gaap:RetainedEarningsMember2023-06-300001484612us-
gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001484612om:SlrTermLoanFacilityMemberus-
gaap:InterestRateFloorMember2024-01-012024-06-300001484612us-gaap:RetainedEarningsMember2022-12-
310001484612om:ConsolesProductMember2023-01-012023-06-3000014846122023-03-310001484612us-
gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberom:SlrRevolverMember2024-01-012024-06-
3000014846122021-10-012024-06-300001484612us-gaap:CostOfSalesMember2024-04-012024-06-3000014846122023-
01-012023-03-310001484612om:UnrealizedLosses12MonthsOrGreaterMember2024-06-300001484612us-
gaap:CostOfSalesMember2023-04-012023-06-300001484612us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001484612us-
gaap:EmployeeStockOptionMember2024-01-012024-06-300001484612us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-
310001484612om:AdditionalTrancheMemberom:SlrRevolverMember2024-01-012024-06-
300001484612om:UnrealizedLosses12MonthsOrGreaterMemberom:USGovernmentSponsoredEnterprisesMember2023-
12-3100014846122023-06-300001484612om:Two Thousand Twenty Equity Incentive Plan Member2024-06-
300001484612us-gaap:USTreasurySecuritiesMember2024-06-
30xbri:purexbri:sharesiso4217:USDiso4217:USDxbri:shares Â UNITED STATES SECURITIES AND EXCHANGE
COMMISSION WASHINGTON, DC 20549 Â FORM 10-Q Â (Mark One) â˜ Â QUARTERLY REPORT PURSUANT TO
SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024
OR â˜ Â TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to Commission File Number: 001-39513 Â Outset Medical, Inc. (Exact Name of
Registrant as Specified in its Charter) Â Delaware 20-0514392 (State or other jurisdiction of incorporation or
organization) (I.R.S. Employer Identification No.) 3052 Orchard Dr. San Jose, California 95134 (Address of principal
executive offices) (Zip Code) Â Registrantâ€™s telephone number, including area code: (669) 231-8200 Â Securities
registered pursuant to Section 12(b) of the Act: Â Title of each class Â Trading Symbol(s) Â Name of each exchange on
which registered Common Stock, par value \$0.001 per share Â OM Â The Nasdaq Stock Market LLC Â Indicate by
check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜ No â˜ Indicate by
check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted
pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit such files). Yes â˜ No â˜ Indicate by check mark whether the
registrant is a large accelerated filer, an accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of â€œlarge accelerated filer,â€œ â€œaccelerated filer,â€œ â€œsmaller
reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Â Large accelerated
filer â˜ Accelerated filer â˜ Â Non-accelerated filer â˜ Smaller reporting company â˜ Â Â Â Â Â Emerging growth company Â â˜ Â Â Â Â If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is
a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜ As of July 31, 2024, the registrant had
52,089,795 shares of common stock, \$0.001 par value per share, outstanding. Â Table of Contents Â Page PART
I. FINANCIAL INFORMATION Â 1 Item 1. Financial Statements (Unaudited) Â 1 Condensed Balance Sheets Â 1
Condensed Statements of Operations Â 2 Condensed Statements of Comprehensive Loss Â 3 Â Condensed Statements
of Stockholdersâ€™ Equity Â 4 Condensed Statements of Cash Flows Â 6 Notes to Unaudited Condensed Financial
Statements Â 7 Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Â
16 Item 3. Quantitative and Qualitative Disclosures About Market Risk Â 22 Item 4. Controls and Procedures Â 22
PART II. OTHER INFORMATION Â 23 Item 1. Legal Proceedings Â 23 Item 1A. Risk Factors Â 23 Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds Â 24 Item 3. Defaults Upon Senior Securities Â 24 Item 4.
Mine Safety Disclosures Â 25 Item 5. Other Information Â 25 Item 6. Exhibits Â 26 Signatures Â 27 Â Â Â Â PART
Iâ€”FINANCIAL INFORMATION Item 1. Financial Statements (unaudited). Outset Medical, Inc. Condensed Balance
Sheets (Unaudited) (in thousands, except per share amounts) Â Â Â June 30, Â Â December 31, Â Â 2024 Â Â
2023 Â Â Â Â Assets Â Â Â Â Current assets: Â Â Â Â Cash and cash equivalents Â \$ 37,859
Â Â \$ 68,509 Â Short-term investments Â Â 156,989 Â Â 134,815 Â Accounts receivable, net Â Â 34,121 Â Â
32,980 Â Inventories Â Â 61,599 Â Â 49,215 Â Prepaid expenses and other current assets Â Â 4,569 Â Â
5,700 Â Total current assets Â Â 295,137 Â Â 291,219 Â Restricted cash Â Â 3,329 Â Â 3,329 Â Property
and equipment, net Â Â 10,873 Â Â 13,273 Â Operating lease right-of-use assets Â Â 4,675 Â Â 5,375 Â
Other assets Â Â 520 Â Â 605 Â Total assets Â \$ 314,534 Â Â \$ 313,801 Â Liabilities and stockholders' equity Â
Â Â Â Â Current liabilities: Â Â Â Â Accounts payable Â \$ 5,255 Â Â \$ 5,827 Â Accrued compensation and
related benefits Â Â 11,431 Â Â 19,005 Â Accrued expenses and other current liabilities Â Â 9,747 Â Â
13,459 Â Accrued warranty liability Â Â 2,199 Â Â 3,712 Â Deferred revenue, current Â Â 13,108 Â Â 11,727
Â Operating lease liabilities, current Â Â 1,693 Â Â 1,593 Â Total current liabilities Â Â 43,433 Â Â 55,323 Â
Accrued interest Â Â 1,762 Â Â 896 Â Deferred revenue Â Â 130 Â Â 101 Â Operating lease liabilities Â Â
3,616 Â Â 4,482 Â Term loans Â Â 196,994 Â Â 130,113 Â Total liabilities Â Â 245,935 Â Â 190,915 Â
Commitments and contingencies (Note 6) Â Â Â Â Stockholders' equity: Â Â Â Â Preferred stock,
\$0.001Â par value; 5,000Â shares authorized, and noÂ shares issued and outstanding as of June 30, 2024 and December
31, 2023 Â Â Â Â Common stock, \$0.001Â par value; 300,000Â shares authorized as of June 30, 2024
and December 31, 2023; 52,084Â and 50,317Â shares issued and outstanding as of June 30, 2024 and December 31,
2023, respectively Â Â 52 Â Â 50 Â Additional paid-in capital Â Â 1,104,994 Â Â 1,084,515 Â Accumulated
other comprehensive income (loss) Â Â (302) Â Â 68 Â Accumulated deficit Â Â (1,036,145) Â Â (961,747) Total
stockholders' equity Â Â 68,599 Â Â 122,886 Â Total liabilities and stockholders' equity Â \$ 314,534 Â Â \$
313,801 Â The accompanying notes are an integral part of these unaudited condensed financial statements. 1 Â Outset

Medical, Inc. Condensed Statements of Operations (Unaudited) (in thousands, except per share amounts) **Three Months Ended June 30, 2024** **2023** **2024** **2023** **Revenue:** **Product revenue** **\$ 19,238** **\$ 29,330** **\$ 39,666** **\$ 57,109** **Service and other revenue** **8,150** **6,710** **15,890** **12,398** **Total revenue** **\$ 27,388** **\$ 36,040** **\$ 55,556** **69,507** **Cost of revenue:** **Cost of product revenue** **10,567** **22,212** **23,148** **43,029** **Cost of service and other revenue** **7,039** **6,125** **14,411** **12,347** **Total cost of revenue** **\$ 17,606** **\$ 28,337** **\$ 37,559** **\$ 55,376** **Gross profit** **\$ 9,782** **\$ 7,703** **\$ 17,997** **\$ 14,131** **Operating expenses:** **Research and development** **9,734** **14,906** **22,369** **28,699** **Sales and marketing** **18,128** **24,985** **39,176** **49,318** **General and administrative** **12,684** **11,290** **24,128** **23,077** **Total operating expenses** **\$ 40,546** **\$ 51,181** **\$ 85,673** **\$ 101,094** **Loss from operations** **(30,764)** **(43,478)** **(67,676)** **(86,963)** **Interest income and other income, net** **2,471** **2,668** **5,569** **5,316** **Interest expense** **(6,010)** **(3,103)** **(11,978)** **(6,045)** **Loss before provision for income taxes** **(34,303)** **(43,913)** **(74,085)** **(87,692)** **Provision for income taxes** **151** **133** **313** **325** **Net loss** **\$ (34,454)** **\$ (44,046)** **\$ (74,398)** **\$ (88,017)** **Net loss per share, basic and diluted** **\$ (0.66)** **\$ (0.90)** **\$ (1.45)** **\$ (1.79)** **Shares used in computing net loss per share, basic and diluted** **51,880** **48,951** **51,391** **49,085** **The accompanying notes are an integral part of these unaudited condensed financial statements.** **2** **Outset Medical, Inc. Condensed Statements of Comprehensive Loss (Unaudited) (in thousands) **Three Months Ended June 30, 2024** **2023** **2024** **2023** **Net loss** **\$ (34,454)** **\$ (44,046)** **\$ (74,398)** **\$ (88,017)** **Other comprehensive (loss) income:** **Unrealized (loss) gain on available-for-sale securities** **(44)** **(280)** **(370)** **171** **Comprehensive loss** **\$ (34,498)** **\$ (44,326)** **\$ (74,768)** **\$ (87,846)** **The accompanying notes are an integral part of these unaudited condensed financial statements.** **3** **Outset Medical, Inc. Condensed Statement of Stockholders' Equity (Unaudited) (in thousands) **Common Stock** **Additional Paid-in** **Accumulated Other Comprehensive** **Accumulated Total Stockholders' Shares** **Amount** **Capital** **Income (Loss)** **Deficit** **Equity** **Balance as of December 31, 2023** **50,317** **\$ 50** **\$ 1,084,515** **\$ 68** **\$ (961,747)** **\$ 122,886** **Issuance of common stock through employee stock purchase plan** **776** **1** **2,079** **2,080** **Issuance of common stock for settlement of RSUs** **607** **1** **294** **295** **Stock option exercises** **2** **6** **6** **6** **Stock-based compensation expense** **8,203** **8,203** **Unrealized loss on available-for-sale securities** **(44)** **(44)** **(326)** **Net loss** **\$ (39,944)** **\$ (39,944)** **Balance as of March 31, 2024** **51,702** **\$ 52** **\$ 1,095,097** **\$ (258)** **\$ (1,001,691)** **\$ 93,200** **Issuance of common stock for settlement of RSUs** **312** **77** **77** **Stock-based compensation expense** **9,820** **9,820** **Unrealized loss on available-for-sale securities** **(44)** **(44)** **Net loss** **\$ (34,454)** **\$ (34,454)** **Balance as of June 30, 2024** **52,084** **\$ 52** **\$ 1,104,994** **\$ (302)** **\$ (1,036,145)** **\$ 68,599** **The accompanying notes are an integral part of these unaudited condensed financial statements.** **4** **Outset Medical, Inc. Condensed Statement of Stockholders' Equity (Unaudited) (in thousands) **Common Stock** **Additional Paid-in** **Accumulated Other Comprehensive** **Accumulated Total Stockholders' Shares** **Amount** **Capital** **Income (Loss)** **Deficit** **Equity** **Balance as of December 31, 2022** **48,465** **\$ 48** **\$ 1,035,456** **\$ (564)** **\$ (788,950)** **\$ 245,990** **Issuance of common stock through employee stock purchase plan** **307** **1** **4,593** **4,594** **Issuance of common stock for settlement of RSUs** **282** **162** **684** **Stock-based compensation expense** **8,538** **8,538** **Unrealized gain on available-for-sale securities** **(43,971)** **(43,971)** **Balance as of March 31, 2023** **49,216** **\$ 49** **\$ 1,049,271** **\$ (113)** **\$ (832,921)** **\$ 216,286** **Issuance of common stock for settlement of RSUs** **165** **1** **1,043** **Stock-based compensation expense** **1,042** **1,043** **Unrealized loss on available-for-sale securities** **(280)** **(280)** **Net loss** **\$ (44,046)** **\$ (44,046)** **Balance as of June 30, 2023** **49,629** **\$ 50** **\$ 1,060,418** **\$ (393)** **\$ (876,967)** **\$ 183,108** **The accompanying notes are an integral part of these unaudited condensed financial statements.** **5** **Outset Medical, Inc. Condensed Statements of Cash Flows (Unaudited) (in thousands) **Six Months Ended June 30, 2024** **2023** **Cash flows from operating activities:** **Net loss** **\$ (74,398)** **\$ (88,017)** **Adjustments to reconcile net loss to net cash used in operating activities:** **Stock-based compensation expense** **18,023** **18,643** **Depreciation and amortization** **2,931** **2,898** **Non-cash lease expense** **700** **603** **Non-cash interest expense** **1,241** **914** **Amortization of premium on investments, net** **(2,928)** **(3,353)** **Provision for inventories** **706** **868** **Loss on disposal of property and equipment** **23** **93** **Allowance for credit losses** **1,813** **87** **Changes in operating assets and liabilities:** **Accounts receivable** **(2,953)** **(8,919)** **Inventories** **(13,214)** **6,114** **Prepaid expenses and other assets** **1,196** **1,196** **Accounts payable** **(544)** **1,682** **Accrued compensation and related benefits** **(7,279)** **(4,058)** **Accrued expenses and other current liabilities** **(3,695)** **(3,720)** **Accrued warranty liability** **(1,513)** **547** **Deferred revenue** **1,410** **2,130** **Operating lease liabilities** **(766)** **(640)** **Net cash used in operating activities** **\$ (79,247)** **\$ (72,932)** **Cash flows from investing activities:** **Purchases of property and equipment** **(474)** **(1,605)** **Purchases of investment securities** **(128,445)** **(97,849)** **Maturities of investment securities** **108,829** **129,250** **Net cash (used in) provided by investing activities** **(20,090)** **29,796** **Cash flows from financing activities:** **Proceeds from stock option exercises and ESPP purchases** **2,163** **6,320** **Proceeds from issuance of term loans, net of issuance costs** **66,524** **Net cash provided by financing activities** **68,687** **6,320** **Net decrease in cash, cash equivalents and restricted cash** **(30,650)** **(36,816)** **Cash, cash equivalents and restricted cash** **\$ (30,650)** **\$ (36,816)**********

equivalents and restricted cash as of beginning of period \$ 71,838 \$ 76,533 Cash, cash equivalents and restricted cash as of end of period \$ 41,188 \$ 39,717 \$ 640 Supplemental cash flow disclosures: Cash paid for income taxes \$ 356 \$ 311 Cash paid for interest \$ 10,102 \$ 5,131 Cash paid for amounts included in the measurement of operating lease liabilities \$ 766 \$ 640 Supplemental non-cash investing and financing activities: Capital expenditures included in accounts payable and accrued expenses \$ 115 \$ 216 Right-of-use assets obtained in exchange for operating lease liabilities \$ 528 Transfer of inventories to property and equipment \$ 148 \$ 148 The accompanying notes are an integral part of these unaudited condensed financial statements. 6 Outset Medical, Inc. Notes to Unaudited Condensed Financial Statements 1. Description of Business Outset Medical, Inc. (the Company) is a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis. Tablo® Hemodialysis System (Tablo), cleared by the U.S. Food and Drug Administration (FDA) for use from the hospital to the home, represents a significant technological advancement designed to transform the dialysis experience for patients and operationally simplify it for providers. Tablo serves as a single enterprise solution designed to be utilized across the continuum of care, allowing dialysis to be delivered anytime, anywhere, and by virtually anyone. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a new holistic approach to dialysis care. The Company's headquarters are located in San Jose, California. Liquidity Since inception, the Company has incurred net losses and negative cash flows from operations. During the six months ended June 30, 2024 and 2023, the Company incurred a net loss of \$74.4 million and \$88.0 million, respectively. As of June 30, 2024, the Company had an accumulated deficit of \$1.0 billion. As of June 30, 2024, the Company had cash, cash equivalents, restricted cash and short-term investments of \$198.2 million. The Company is subject to certain covenants limiting or restricting its ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Management expects to continue to incur significant expenses for the foreseeable future and to incur operating losses in the near term while the Company makes investments to support its anticipated growth. Management believes that the Company's existing cash, cash equivalents, short-term investments, cash generated from sales, and proceeds received from the debt financing described in Note 7, will be sufficient to meet its anticipated needs for at least the next 12 months from the issuance date of the accompanying condensed financial statements. Basis of Presentation The accompanying condensed financial statements are unaudited and have been prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) and on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, that are necessary for the fair statement of the Company's financial position, results of operations, comprehensive loss, and cash flows for the interim periods presented. The financial data and the other financial information disclosed in these notes to the condensed financial statements related to the three- and six-month periods are also unaudited. The results of operations for the three and six months ended June 30, 2024 are not necessarily indicative of the results of operations to be anticipated for any other future annual or interim period. The condensed balance sheet as of December 31, 2023 included herein was derived from the audited financial statements as of that date. These unaudited condensed financial statements should be read in conjunction with the Company's audited financial statements and related notes for the year ended December 31, 2023, which are included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed with the Securities and Exchange Commission (SEC) on February 21, 2024 (2023 Annual Report). All share amounts disclosed in the notes to the condensed financial statements are rounded to the nearest thousand except for per share data. 2.

Summary of Significant Accounting Policies Recently Issued Accounting Pronouncements In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (ASU 2023-07), which requires that an entity disclose significant segment expenses impacting profit and loss that are regularly provided to the chief operating decision maker. The update is required to be applied retrospectively to prior periods presented, based on the significant segment expense categories identified and disclosed in the period of adoption. This ASU guidance is effective for our Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent interim periods, with early adoption permitted. The Company is currently evaluating the impact of the adoption of ASU 2023-07 on its financial statements and disclosures. In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (ASU 2023-09), which requires that an entity disclose specific categories in the effective tax rate reconciliation as well as provide additional information for reconciling items that meet a quantitative threshold. Further, this ASU requires certain disclosures of state versus federal income tax expense and taxes paid. This ASU is effective for our Annual Report on Form 10-K for the year ended December 31, 2025, with early adoption permitted. The Company does not expect the adoption of ASU 2023-09 to have a material impact on its financial statements. 7 In March 2024, the SEC adopted rules intended to enhance and standardize climate-related disclosures in registration statements and annual reports. The new rules will require disclosure of material climate-related risks, including the material impacts of these risks to the Company, the quantification of material impacts to the Company as a result of severe weather events and other natural conditions and Board of Directors' oversight and risk management activities. The new rules follow a compliance phase-in timeline based on a company's filing status. Large accelerated filers and accelerated filers (other than smaller reporting companies) are required to first incorporate such disclosures for fiscal years 2025 and 2026, respectively, followed by greenhouse gas-related disclosures, if material, for fiscal years 2026 and 2027, respectively. Smaller reporting companies are required to first incorporate such disclosures for fiscal year 2027 and are not required to report greenhouse gas emissions data. In April 2024, the SEC determined to voluntarily stay the final rules pending certain legal challenges. The Company is currently evaluating the impact of these new rules on its financial statements and disclosures. Significant Accounting Policies There have been no new or material changes to the Company's significant accounting policies as described in its 2023 Annual Report that have had a material impact on the Company's condensed financial statements and related notes. 3. Revenue and Deferred Revenue Disaggregation of Revenue Revenue by source consists of the following (in thousands): Three Months Ended June 30, \$ 16,371 \$ 38,547 Consumables \$ 12,077 \$ 9,646 \$ 23,295 \$ 18,562 Total product revenue \$ 19,238 \$ 29,330 \$ 39,666 \$ 57,109 Service and other revenue \$ 8,150 \$ 6,710 \$ 15,890 \$ 12,398 Total revenue \$ 27,388 \$ 36,040 \$ 55,556 \$ 69,507 Remaining Performance Obligations and Contract Liabilities As of June 30, 2024, the aggregate amount of the transaction price allocated to the remaining performance obligations related to customer service contracts that are

unsatisfied or partially unsatisfied was \$13.2 million, which is recorded as deferred revenue on the Company's condensed balance sheets. Of that amount, \$13.1 million will be recognized as revenue during the next 12 months and \$0.1 million thereafter. The contract liabilities consist of deferred revenue which represents payments received in advance of revenue recognition. Revenue under these agreements is recognized over the related service period. During the three and six months ended June 30, 2024, the Company recognized \$3.3 million and \$8.8 million of previously deferred revenue, respectively. 8. Fair Value Measurements The following tables summarize the Company's financial assets measured at fair value on a recurring basis by level within the fair value hierarchy (in thousands):

June 30, 2024 ValuationHierarchy AmortizedCosts GrossUnrealizedHoldingGains GrossUnrealizedHoldingLosses AggregateFair Value Assets: Cash equivalents: Money market funds Level 1 \$ 18,556 \$ 18,556 Short-term investments: U.S. Treasury securities Level 1 \$ 90,329 \$ 90,329 U.S. government-sponsored enterprises debt securities Level 2 \$ 13,377 \$ 13,377 U.S. government-sponsored enterprises U.S. government-sponsored enterprises debt securities Level 2 \$ 48,089 \$ 48,057 Corporate debt Level 2 \$ 13,362 \$ 5,495 Commercial paper Level 2 \$ 5,495 Total cash equivalents and short-term investments \$ 175,846 \$ 11 \$ (312) \$ 175,545 December 31, 2023 ValuationHierarchy AmortizedCosts GrossUnrealizedHoldingGains GrossUnrealizedHoldingLosses AggregateFair Value Assets: Cash equivalents: Money market funds Level 1 \$ 44,883 \$ 44,883 Short-term investments: U.S. Treasury securities Level 1 \$ 53,790 \$ 53,790 U.S. government-sponsored enterprises debt securities Level 2 \$ 29,645 \$ 29,631 Corporate debt Level 2 \$ 53,816 \$ 33,214 Commercial paper Level 2 \$ 18,097 \$ 56 Total cash equivalents and short-term investments \$ 179,629 \$ 143 \$ (74) \$ 179,698 As of June 30, 2024, the remaining contractual maturities for available-for-sale securities were one month to sixteen months. The following tables present the breakdown of the available-for-sale debt securities with unrealized losses as of June 30, 2024, and December 31, 2023 (in thousands): June 30, 2024 Unrealized losses less than 12 months Unrealized losses 12 months or greater Total Fair Value Unrealized Losses Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. Treasury securities \$ 78,734 \$ (253) \$ 78,734 \$ (253) U.S. government-sponsored enterprises debt securities \$ 7,017 \$ (12) \$ 3,971 \$ (7) \$ 10,988 \$ (19) Corporate debt \$ 34,919 \$ (37) \$ 34,919 \$ (37) Commercial paper \$ 5,493 \$ (3) \$ 5,493 Total \$ 126,163 \$ (305) \$ 3,971 \$ (7) \$ 130,134 December 31, 2023 Unrealized losses less than 12 months Unrealized losses 12 months or greater Total Fair Value Unrealized Losses Fair Value Unrealized Losses U.S. Treasury securities \$ 8,416 \$ (16) \$ 17,925 \$ (16) \$ 26,341 \$ (32) U.S. government-sponsored enterprises debt securities \$ 18,757 \$ (22) \$ 8,488 \$ (16) \$ 27,245 \$ (38) Corporate debt \$ 11,291 \$ (4) \$ 11,291 \$ (4) Total \$ 38,464 \$ (42) \$ 26,413 \$ (32) \$ 64,877 \$ (74) The unrealized losses on the Company's available-for-sale debt securities were caused by interest rate increases. The contractual terms of those investments do not permit the issuer to settle the securities at a price less than the amortized cost basis of the investments. As of June 30, 2024, the Company does not intend to sell the investments, and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be at maturity. Additional factors considered in determining the treatment of unrealized losses include the financial condition and near-term prospects of the investee, the extent of the loss related to the credit of the issuer, and the expected cash flows from the security. For the three and six months ended June 30, 2024 and 2023, the Company did not recognize credit loss related to available-for-sale debt securities.

5. Balance Sheet Components

Cash, Cash Equivalents and Restricted Cash As of June 30, 2024 and December 31, 2023, the restricted cash balance of \$3.3 million, was related to collateral for the Company's building leases in San Jose, CA and Tijuana, Mexico. The following table provides a reconciliation of cash, cash equivalents and restricted cash that sum to the total of the amounts shown in the accompanying condensed statements of cash flows (in thousands): June 30, 2024 Cash and cash equivalents \$ 37,859 \$ 36,388 Restricted cash \$ 3,329 Total cash, cash equivalents and restricted cash \$ 41,188 \$ 39,717 Accounts Receivable Accounts receivable are recorded at invoice value, net of any allowance for credit losses. The allowance for credit losses is based on the Company's assessment of its best estimate of the amount of credit losses in customer accounts. The Company regularly reviews the allowance by considering factors such as existing contractual payment terms, historical collection experience, the financial position of the customer and information provided by credit rating services, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. The Company writes off accounts receivable when the Company has exhausted collection efforts without success, and payments subsequently received on such receivables are credited to the allowance in the period the payment is received. Credit losses from continuing operations have consistently been within management's expectations. The following table presents the activity in the Company's allowance for credit losses (in thousands): Balance as of December 31, 2023 \$ 203 Increase in allowance \$ 1,820 Write-offs \$ (7) Balance as of June 30, 2024 \$ 2,016 Inventories Inventories consist of the following (in thousands): June 30, December 31, 2024 2023 Raw materials \$ 23,340 \$ 18,706 Work in process \$ 11,864 \$ 8,728 Finished goods \$ 26,395 \$ 21,781 Total inventories \$ 61,599 \$ 49,215 Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consist of the following (in thousands): June 30, December 31, 2024 2023 Inventory \$ 3,683 \$ 3,395 Research and development expenses \$ 281 \$ 1,050 Professional services \$ 896 \$ 1,153 Customer rebates \$ 1,588 \$ 2,100 Other \$ 3,299 \$ 5,761 Total accrued expenses and other current liabilities \$ 9,747 \$ 13,459 6. Commitments and Contingencies

Litigation From time to time, the Company may become involved in legal proceedings or investigations, which could have an adverse impact on its reputation, business and financial condition and divert the attention of the Company's management from the operation of the Company's business. The Company is not presently a party to any legal proceedings that, if determined adversely to the Company, would individually or taken together have a material adverse effect on its business, results of operations, financial condition or cash flows. Indemnification In the ordinary course of business, the Company often includes standard indemnification provisions in its arrangements with

its partners, customers and suppliers. Pursuant to these provisions, the Company may be obligated to indemnify such parties for losses or claims suffered or incurred in connection with its service, breach of representations or covenants, intellectual property infringement or other claims made against such parties. These provisions may limit the time within which an indemnification claim can be made. It is not possible to determine the maximum potential amount under these indemnification obligations due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each particular agreement. To date, the Company has not incurred any material costs as a result of such indemnification obligations and has not accrued any liabilities related to such obligations in these financial statements.

7. Term Loan

The term loan consists of the following (in thousands):

Category	Amount
Principal of term loans	\$ 200,000
Unamortized debt discount	\$ 133,476
Total	\$ 333,476

On November 3, 2022 (the Closing Date), the Company entered into two senior secured credit facilities, which collectively provide for borrowings of up to \$300.0 million as follows:

- (i) up to a \$250.0 million term loan facility pursuant to a loan and security agreement (the SLR Loan Agreement) among SLR Investment Corp., as collateral agent (Agent), the lenders from time to time party thereto (the Term Loan Lenders) and the Company (the SLR Term Loan Facility), and
- (ii) up to a \$50.0 million asset-based revolving credit facility pursuant to a credit agreement (the SLR Revolving Credit Agreement, together with the SLR Loan Agreement, the SLR 11 Credit Facility Agreements) among Gemono Healthcare Finance, LLC d/b/a SLR Healthcare ABL, as lender (ABL Lender), and the Company (the SLR Revolver, together with the SLR Term Loan Facility, the SLR Credit Facilities).

The maximum amount the Company is permitted to borrow under the SLR Credit Facilities is subject to certain overall borrowing limitations that are tied to achieving certain specified revenue milestones and limit the maximum principal amount outstanding under the SLR Credit Facilities. As of June 30, 2024, the Company borrowed an aggregate principal amount of \$200.0 million under the SLR Term Loan Facility, the full amount available under the borrowing limitations.

SLR Term Loan Facility

Under the SLR Loan Agreement, as subsequently amended on December 11, 2023, the Term Loan Lenders agreed to extend term loans to the Company in an aggregate principal amount of up to \$250.0 million, comprised of (i) a term loan of \$100.0 million (the Term A Loan), (ii) term loans in an aggregate principal amount of up to \$100.0 million that was provided for in two increments, one of \$33.5 million (the Term B-1 Loan) and one of \$66.5 million (the Term B-2 Loan) and (iii) one or more term loans in an aggregate principal amount of up to \$50.0 million (Term C Loans). Each Term A Loan, Term B Loan and Term C Loan is referred to single as a Term Loan and are referred to collectively as the Term Loans. The Term C Loans are subject to compliance with the borrowing limitations, Term Loan Lenders' credit approval and the achievement of a specified net revenue milestone on or before June 30, 2025 and if available, would remain available for funding until one business day prior to November 1, 2027. Any principal amount outstanding under the Term Loans will accrue interest at a rate per annum equal to one-month term Secured Overnight Financing Rate (term SOFR) (subject to a 2.75% floor), plus 5.15% (10.48% as of June 30, 2024), payable monthly in arrears. The Company is permitted to make interest-only payments on the Term Loans through November 30, 2026. Any principal amounts outstanding under the Term Loans, if not repaid sooner, are due and payable on November 1, 2027 (the Maturity Date). The Company is obligated to pay Agent (i) a non-refundable facility fee in the amount of \$750,000 in respect of the Term A Loan, (ii) a non-refundable facility fees in the aggregate amount of \$750,000 in respect of the Term B-1 and B-2 Loans and (iii) a non-refundable facility fee in the amount of \$375,000 in respect of the Term C Loan, to be due and payable upon the earliest to occur of (a) the funding of the first Term C Loan, (b) one day prior to the Maturity Date and (c) the prepayment of the Term Loans. In addition, the Company is obligated to pay a final fee equal to 4.75% of the aggregate amount of the Term Loans funded, such final fee to be due and payable upon the earliest to occur of (i) the Maturity Date, (ii) the acceleration of the Term Loans and (iii) the prepayment of the Term Loans. The Company may voluntarily prepay the outstanding Term Loans, subject to a prepayment premium of (i) 3.0% of the principal amount of the Term Loan, if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2.0% of the principal amount of the Term Loan, if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1.0% of the principal amount of the Term Loan if prepaid after the second anniversary of the Closing Date and prior to the Maturity Date.

SLR Revolver

The SLR Revolving Credit Agreement provides for an asset-based revolving credit facility with aggregate revolving commitments of \$25.0 million (the Initial Revolver Commitment). The Company may request to increase the aggregate revolving commitments by \$25.0 million (the Additional Tranche) to an aggregate amount of \$50.0 million, subject to ABL Lender's approval. Amounts available to be drawn under the SLR Revolver are equal to the lesser of (i) outstanding revolving commitments under the SLR Revolving Credit Agreement and (ii) a borrowing base (the Borrowing Base) equal to the sum of (a) 85% of eligible accounts receivable, plus (b) 25% of eligible inventory (not to exceed the lesser of 50% of the Borrowing Base and \$5.0 million), minus (c) customary reserves, minus (d) unposted cash. As of June 30, 2024, no amounts were outstanding under the SLR Revolver. As a result of the overall borrowing limitations set forth in the SLR Credit Facilities, amounts under the SLR Revolver are not currently available. As of June 30, 2024, the Company has not requested or received ABL Lender's approval of the Additional Tranche. Any principal amount outstanding under the SLR Revolver will accrue interest at a rate per annum equal to one-month term SOFR (subject to a 2.75% floor), plus 3.20%, payable monthly in arrears. Interest on any borrowing is payable monthly. The Company is obligated to pay Lender (i) a non-refundable facility fee in the amount of \$187,500 in respect of the Initial Revolver Commitment, (ii) a non-refundable facility fee in the amount of \$187,500 in respect of the Additional Tranche, to be due and payable upon activation of the Additional Tranche, (iii) a commitment fee of 0.50% per annum of the average daily unused portion of the then commitment amount, payable monthly and (iv) a collateral monitoring fee of 0.10% per month of the average daily Borrowing Base during the prior month, payable monthly. The Company may terminate the SLR Revolver at any time, subject to a termination fee of (i) 2.0% of the aggregate revolving commitments then in effect, if terminated prior to or on the first anniversary of the Closing Date, (ii) 1.0% of the aggregate revolving commitments then in effect, if terminated after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 0.5% of the aggregate revolving commitments then in effect, if terminated after the second anniversary of the Closing Date through and including the third anniversary of the Closing Date. Such termination fee is waived if the SLR Revolver is terminated after the third anniversary of the Closing Date and prior to the Maturity Date. Subject to customary exceptions and restrictions, the Company may borrow, repay and reborrow varying amounts under the SLR Revolver at any time subject to the overall borrowing limitations. If at any time the outstanding amount under the SLR Revolver exceeds the lesser of (i) the aggregate revolving commitments then in effect and (ii) the Borrowing Base then in effect, the Company will be required to prepay outstanding amounts under the SLR Revolver. The SLR Revolver shall expire on November 1, 2027.

Other Terms of the SLR Credit Facilities

As security for its obligations under the SLR

Credit Facilities, the Company granted Agent, for the benefit of the Term Loan Lenders, and ABL Lender a security interest in substantially all of the assets of the Company, including the Company's intellectual property, subject to certain exceptions. The SLR Credit Facility Agreements contain customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on the Company's ability to dispose of its business or property, to change its line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on its property or to pay any dividends or other distributions on capital stock. The agreements also include a financial covenant that, beginning with the fiscal quarter ending December 31, 2023, the Company must either (i) maintain certain levels of cash and cash equivalents in accounts subject to control agreements in favor of Agent and ABL Lender of at least 50% of the sum of (a) the outstanding obligations under the Term Loans (as defined below) and (b) the amount of the Company's accounts payable that have not been paid within 120 days from the invoice date thereof or (ii) generate net product and product related revenue in excess of specified amounts and maintain gross profit margins in excess of specified percentages, in each case, for applicable measuring periods. In addition, the SLR Credit Facility Agreements contain customary events of default that entitle Agent, under the SLR Loan Agreement, and ABL Lender, under the SLR Revolving Credit Agreement, to cause the Company's indebtedness under the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable, to become immediately due and payable, and to exercise remedies against the Company and the collateral securing the obligations owed under the applicable SLR Credit Facility Agreement. Under the SLR Credit Facility Agreements, an event of default will occur if, among other things, the Company fails to make payments under either SLR Credit Facility Agreement, the Company breaches covenants under either SLR Credit Facility Agreement, subject to specified cure periods with respect to certain breaches, the Agent or ABL Lender, as applicable, determine that a material adverse change has occurred under the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable, or the Company or its assets become subject to certain legal proceedings, such as bankruptcy proceedings. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4.0% per annum will apply to all obligations owed under the SLR Credit Facility Agreements. The debt issuance costs and the facility fees related to the Term A and B Loans were recorded as a direct deduction from the term loans balance on the balance sheets and are being recognized as non-cash interest expense over the term of the loans using the effective interest method, along with the final payment fee. The facility fees related to the Initial Revolver Commitment were recorded as deferred financing costs and are being recognized as non-cash interest expense over their respective commitment period using straight-line method.

8. Equity Incentive Plan

Equity Incentive Plans

As of June 30, 2024, 3,247,000 shares were reserved for future issuance under the 2020 Equity Incentive Plan (2020 Plan). Employee Share Purchase Plan (ESPP)

As of June 30, 2024, 931,000 shares of common stock were reserved for issuance in connection with the current and future offering periods under the ESPP.

13. Restricted Stock

The Company issues restricted stock units (RSUs) and performance stock units (PSUs), both of which are considered restricted stock. The Company grants restricted stock pursuant to the 2020 Plan and satisfies such grants through the issuance of new shares. RSUs are share awards that, upon vesting, will deliver to the holder shares of our common stock. RSUs with a service-based vesting condition granted to a grantee, beginning in February 2022, generally vest over a three-year period as follows either: (i) 25% on the first anniversary of the original vesting date, 25% quarterly over the course of the second year, and 50% quarterly over the course of the third year, or (ii) 33% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining two years. Annual RSUs granted to non-executive employees in 2024 vest over a two-year period at a rate of 50% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining one year. Prior to February 2022, RSUs with a service-based vesting condition granted to a grantee generally vest at a rate of 25% on the first anniversary of the original vesting date, with the balance vesting quarterly over the remaining three years. Since 2022, the Company has granted a mix of 50% PSUs and 50% RSUs to its CEO, and a mix of 20% PSUs and 80% RSUs to its other executive officers and certain other senior leaders on an annual basis. The PSUs are earned and vest based on achievement against two metrics: (i) Home PSUs are earned based on the number of patients treating at home on Tablo as of the end of the second or third year following the grant date (Year 2 or Year 3), with earned units vesting either (i) 50% after certification of achievement following the end of Year 2 and 50% at the end of Year 3 or (ii) 100% after certification of achievement following the end of Year 3 (performance-based vesting conditions). (ii) Relative TSR PSUs are earned based on the Company's relative total stockholder return (relative TSR) at the end of a two-year or three-year performance period as compared to companies in a pre-determined index of medical device companies, in each case, with 100% of earned units vesting on, or after certification of achievement following, the third anniversary of the grant date (market-based vesting conditions). The number of units earned varies based on actual performance as follows: (i) from 0% to 200% (250% for the CEO) of the target number of the Home PSUs granted, (ii) from 75% to 150% (250% for the CEO) of the target number of Relative TSR PSUs granted in 2022 and 2023 and (iii) from 0% to 200% (250% for the CEO) of the target number of Relative TSR PSUs granted in 2024. The grant date for the Home PSUs is not considered established until the Compensation Committee of the Board approves the target and it is communicated to the award recipients, which then triggers the service inception date, the fair value of the awards, and the associated expense recognition period. Once the grant date for the Home PSUs has been established, the related stock-based compensation expense is recorded based on the forecasted performance, which is reassessed each reporting period based on the probability of achieving the performance conditions. In 2024, the Company also granted a new type of PSU award to executive officers and certain other senior leaders which is earned and vests based on appreciation of the Company's stock price above pre-determined stock price triggers or achievement of specified operating income targets over a performance period of up to three years.

Stock-Based Compensation Expense

The following table sets forth stock-based compensation expense included in the accompanying condensed statements of operations (in thousands):

Period	Stock-Based Compensation Expense
Three Months Ended June 30, 2024	\$ 2,293
Three Months Ended June 30, 2023	\$ 2,824
Six Months Ended June 30, 2024	\$ 5,439
Six Months Ended June 30, 2023	\$ 4,625

Research and development

Cost of revenue

Sales and marketing

General and administrative

Total stock-based compensation expense

Income Taxes

For each of the three and six months ended June 30, 2024 and 2023, the Company incurred an income tax provision of an insignificant amount, which primarily related to foreign income taxes related to the Company's Mexico operations. The U.S. federal and state net deferred tax assets have been fully offset by a valuation allowance, as the Company believes it is not more likely

than not that the deferred tax assets will be realized.

10. Net Loss Per Share

The following outstanding potentially dilutive shares were excluded from the calculation of diluted net loss per share due to their anti-dilutive effect (in thousands):

Category	Shares
Three and Six Months Ended June 30, 2024	1,615
Restricted stock units	2,162
Performance stock units	4,777
Shares committed under ESPP	2,707
Shares committed under Warrant	318
Total	6,827
Less: Total Common Stock Outstanding	5,104
Total Diluted Shares	11

11. Workforce reduction

In order to improve operational efficiencies, reduce operating expenses and streamline its overall organizational structure, the Company recently implemented two organizational restructurings. At the beginning of the fourth quarter of 2023, the Company began a workforce reduction which was substantially completed by the end of 2023, incurring restructuring charges of \$2.5 million in the fourth quarter of 2023 for employee severance and other termination benefits. In May 2024, the Company implemented an additional workforce reduction plan (the May 2024 workforce reduction plan) that was estimable and probable as of March 31, 2024 and, as a result, recognized restructuring charges of \$2.7 million in the first quarter of 2024 for employee severance and other termination benefits. The following table sets forth severance and related benefits charges related to the May 2024 workforce reduction plan included in the accompanying condensed statements of operations (in thousands):

Category	Amount
Cost of revenue	\$ 213
Research and development	1,099
Sales and marketing	1,011
General and administrative	455
Total	\$ 2,778

The changes in liabilities resulting from the restructuring accruals, which were recorded in accrued compensation and related benefits on the accompanying condensed balance sheet, were as follows (in thousands):

Category	Amount
Balance as of December 31, 2023	\$ 854
Charges	2,778
Payments and other adjustments	(2,889)
Balance as of June 30, 2024	\$ 743

12. Subsequent Event

In connection with steps the Company is taking to help optimize its commercial organization, and to help improve operational efficiencies and reduce operating expenses to align with anticipated revenue growth, in August 2024, the Company initiated an additional restructuring plan primarily impacting its commercial organization (the August 2024 restructuring plan). The Company expects to incur approximately \$1.3 million of restructuring charges in the third quarter of 2024 for employee severance and other termination benefits.

15. Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion of our financial condition and results of operations should be read together with our unaudited condensed financial statements and related notes and other financial information included elsewhere in this Quarterly Report, as well as our audited financial statements and notes thereto and the related Management's Discussion and Analysis of Financial Condition and Results of Operations included in our 2023 Annual Report. As used in this Quarterly Report, references to the "Company," "we," "us," "our," "you" or similar terms refer to Outset Medical, Inc. In addition to historical financial information, this discussion and other parts of this report contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical fact contained in this Quarterly Report are forward-looking statements. In some cases, you can identify these statements by forward-looking words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "would," "project," "predict," "plan," "expect" or the negative or plural of these words or similar expressions. The forward-looking statements in this report are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Such risks and uncertainties include those described throughout this Quarterly Report, including in this discussion as well as in the section titled "Risk Factors" under Part II, Item 1A below and in Part I, Item 1A, "Risk Factors" and in Part II, Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our 2023 Annual Report. The forward-looking statements in this Quarterly Report are based upon information available to us as of the date of this Quarterly Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements, like all statements in this report, speak only as of their date, and, except as required by law we undertake no obligation to update or revise these statements, whether as a result of any new information, future developments or otherwise. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Overview

Our technology is designed to elevate the dialysis experience for patients and help providers overcome traditional care delivery challenges. Requiring only an electrical outlet and tap water to operate, our Tablo® Hemodialysis System (Tablo) frees patients and providers from the burdensome infrastructure required to operate traditional dialysis machines. The integration of water purification and on-demand dialysate production in a single 35-inch compact console enables Tablo to serve as a dialysis clinic on wheels. With a simple-to-use touchscreen interface, two-way wireless data transmission and a proprietary data analytics platform, Tablo is a holistic approach to dialysis care. Unlike existing hemodialysis machines, which have limited clinical versatility across care settings, Tablo can be used seamlessly across multiple care settings and a wide range of clinical applications. Tablo is cleared by the FDA for use in the hospital, clinic, or home setting. Tablo leverages cloud technology, making it possible for providers to monitor devices remotely, view treatment data, perform patient and population analytics, and automate clinical recordkeeping. Tablo's wireless connectivity enables us to release training, new features and enhancements over-the-air without interventions by field service engineers (FSEs). Tablo's connectedness allows continuous streaming of over 500,000 device performance data points to the cloud for every treatment. We use this data, in conjunction with our diagnostic and predictive algorithms, to monitor device performance, identify and diagnose failures and, in some instances, predict and prevent potential future device failures or malfunctions. In effect, this contributes to a reduction in service hours and an increase in device uptime. We have generated meaningful evidence to demonstrate that providers can realize significant operational efficiencies, including reducing the cost of their dialysis programs by up to 80% in the intensive care unit. In addition, Tablo has been shown to deliver robust clinical care. In studies and surveys we have conducted, patients have reported quality of life benefits on Tablo compared to other dialysis machines. We believe Tablo empowers patients, who have traditionally been passive recipients of care, to regain agency and ownership of their treatment. Driving adoption of Tablo in the acute care setting has been our primary focus to date. We have invested in growing our economic and clinical evidence, built a veteran sales and clinical support team with significant expertise, and implemented a comprehensive training and customer experience program. Our experience in the acute care market has demonstrated Tablo's clinical flexibility and operational versatility, while also delivering meaningful cost savings to

the providers. We plan to continue leveraging our commercial infrastructure to broaden our installed base in the acute care market, as well as driving utilization and fleet expansion with our existing customers. 16 Å Tablo is also utilized for home-based dialysis. We believe our ability to reduce training time, patient dropout, and the supplies and infrastructure required to deliver dialysis in the home can drive efficiency and economic improvements to the home care model. In our home investigational device exemption (IDE) trial, patients reported specific quality of life improvements compared to their experience on the incumbent home dialysis machine. To penetrate this market successfully, we continue to focus on refining our home distribution, logistics and support systems to help ensure they are ready for scale. We are also working with providers, patients, and payors to increase awareness and adoption of transitional care units (TCUs) as a bridge to home-based therapy. We generate revenue from the placement of Tablo consoles along with accessories, and shipping and handling charged to customers, which revenue is recognized up-front. We also earn recurring revenue from sales of consumables, including Tablo cartridges, and services, which generates significant total revenue over the life of Tablo console. Our total revenues were \$27.4 million and \$36.0 million for the three months ended June 30, 2024 and 2023, respectively, and \$55.6 million and \$69.5 million for the six months ended June 30, 2024 and 2023, respectively. We primarily sell our solutions through our direct sales organization, which covers most major metropolitan markets in the United States. Our sales organization is comprised of our capital sales team, responsible for generating new customer demand for Tablo, and our clinical sales team, responsible for driving utilization and fleet expansion of Tablo at existing customer sites. In addition, our field service team provides maintenance services and product support to our customers. Our field sales and service teams represent 52% of our total full-time employees as of June 30, 2024. The same sales organization and field service team drive Tablo penetration in both the acute and home markets. We believe the ability to leverage one team to serve both markets will result in significant productivity and cost optimization as we continue to scale our business. Recent Developments In July 2023, we received a warning letter (the Warning Letter) from the FDA that raised two observations. The first observation asserted that certain content reviewed by the FDA and found on our website promoted CRRT, a modality outside of the current indications for Tablo. The second observation asserted that TabloCart with Prefiltration requires prior 510(k) clearance for marketing authorization. TabloCart with Prefiltration is an accessory to Tablo launched in the third quarter of 2022. We believe the concern raised by the first observation regarding CRRT promotion has been effectively addressed through a thorough review of existing promotional materials and practices. We believe the concern raised by the second observation regarding TabloCart with Prefiltration has also been effectively addressed. Although we evaluated TabloCart with Prefiltration prior to marketing and distributing the product and concluded that no marketing authorization was necessary, we paused distribution of TabloCart with Prefiltration pending the FDA's review and clearance of a 510(k) application that we submitted in September 2023. In early May 2024, we received 510(k) clearance from the FDA for TabloCart with Prefiltration, and we have resumed distribution of TabloCart with Prefiltration. We believe we have now taken appropriate measures to fully address the matters raised in the Warning Letter. Key Factors Affecting Our Performance We believe that our financial performance has been and in the foreseeable future will continue to be primarily driven by the following factors. While we believe each of these factors presents significant opportunities for our business, they also pose important challenges that we must successfully address in order to sustain our growth and improve our results of operations. Our ability to successfully address the factors below is subject to various risks and uncertainties, including those described in the section titled "Risk Factors." Market Acceptance of Tablo in Acute Setting We plan to further broaden our installed base by continuing to target national and regional integrated delivery networks and health systems, sub-acute long-term acute care hospitals (LTACHs) and skilled nursing facilities (SNFs). In addition, we focus on driving utilization and fleet expansion with existing customers by providing an exceptional user experience delivered through our commercial team and a steady release of software enhancements that amplify Tablo's operational reliability and clinical versatility. Our ability to successfully execute on this strategy, and thereby increase our revenue in the acute market, will depend on several factors. These factors include our ability to recover from the adverse impact in the field from the Warning Letter as we resume distribution of TabloCart with Prefiltration, as well as the success of our initiatives to optimize our commercial organization, infrastructure and sales processes to support the growth of our business in the acute care market as we focus more heavily on enterprise selling and transition beyond earlier stage adoption of Tablo. Expansion of Tablo within the Home Setting We believe that a significant growth opportunity exists within the home hemodialysis market. We are partnering with innovative dialysis clinic providers, health systems and other adjacent healthcare providers who are motivated to grow their home hemodialysis population, and who share our vision of creating a seamless and supported transition to the home. We are also investing in market development over the longer term to expand the home hemodialysis market itself. The expansion of the home hemodialysis market and our ability to penetrate this market will be an important factor in driving the future growth of our business. In addition, the success of our efforts to expand within the home market, help grow new home programs and increase our revenue generated from 17 Å home-based dialysis on the timeline that we anticipate will depend on several factors. These factors include the success of our initiatives to optimize and further evolve our commercial organization, infrastructure and sales processes as we scale our business in the home market. Gross Margin Expansion Our ability to expand our gross margins depends on: first, our ability to reduce the cost of Tablo consoles; second, our ability to continue to sell Tablo cartridges, services, and accessories for Tablo consoles; and third, our ability to reduce the cost of service. Over the past several years, we have moved the production of Tablo consoles and a majority of Tablo cartridges in-house to our manufacturing facility in Tijuana, Mexico which we operate in collaboration with TACNA as part of our cost reduction activities. This has helped further our long-term gross margin expansion and supply continuity strategies while reducing the costs of Tablo console production and improving the flexibility of our operations. We will continue our cost reduction activities by using our design, engineering, supply chain and manufacturing capabilities to help further advance and improve the efficiency of our manufacturing processes, lowering the cost of parts and components and lowering our costs of production. Further, we will continue to utilize our cloud-based data system, as well as enhanced product performance, to better support our field service team and drive down service costs per console. In addition, our ability to expand gross margins will depend in part on our ability to control the average selling prices of our products and services, including by selling higher-margin accessories, consumables and services. Our ability to expand gross margins depends on our ability to successfully execute these strategies. Profitability Initiatives Our ability to achieve and sustain profitability depends on several key factors: first, our ability to grow our revenue while expanding gross margins, as discussed above; second, our ability to optimize operating expenses; and third, our ability to optimize working capital. We have undertaken various initiatives designed to improve operational efficiencies, reduce operating expenses to align with anticipated levels of revenue growth and streamline our overall cost structure, including two organizational restructurings

implemented in the fourth quarter of 2023 and second quarter of 2024. In connection with steps we are taking to help optimize our commercial organization, in August 2024, we initiated an additional restructuring plan primarily impacting our commercial organization. We are also taking steps to improve our ability to efficiently manage working capital, including inventory. Our ability to transition to profitability will depend on the success of our efforts to optimize spending and working capital, including inventory. Impacts of Macroeconomic Factors Global macroeconomic conditions, including inflationary pressures, rising interest rates, increased labor costs, staffing shortages and global supply chain disruptions, may impact our business and results of operations, and those of our customers, manufacturing partners and suppliers. As the duration and severity of these macroeconomic conditions remain uncertain and depend on various factors, we cannot predict what effects these macroeconomic conditions will ultimately have on our business and results of operations, our customers, or our suppliers. Beginning in the third quarter of 2023, we began to observe an increasing number of our existing and prospective customers deferring their decisions to purchase Tablo in an environment of rising interest rates and more cautious capital spending. These deferrals served to elongate our sales cycle and the timing of delivery and installations, which, in turn, contributed to an adverse impact on our bookings and revenues starting in the second half of 2023, and we expect these negative impacts to continue through at least the remainder of 2024. Beginning in 2022, our existing and prospective customers faced shortages of skilled nurses and other clinical personnel as well as increased labor costs, combined with economic pressures resulting from general economic and financial market conditions, primarily escalating inflation, tightening hospital operating budgets and increased scrutiny of capital purchase decisions, all of which generally have the effect of lengthening the average sales cycle and elongating the timing of installations. These factors negatively impacted our customer base on pipeline development and installation schedules, which, in turn, negatively impacted our bookings, delayed our shipments and adversely impacted our revenues for 2022 and, to a lesser extent, 2023. We have generally seen some stabilization in these challenging labor market dynamics for healthcare providers during 2023 and thereafter as compared to 2022. Moreover, we believe Tablo offers automation and ease-of-use benefits over traditional machines that can enhance our existing and potential customers' ability to support their patient populations despite staffing shortages. However, if our customers continue to face prolonged periods of rising interest rates, capital budget constraints, volatility, uncertainty, staffing shortages, cash flow challenges, rising costs and other financial pressures, whether due to general macroeconomic conditions, cybersecurity events or otherwise, it could ultimately adversely impact our ability to expand existing customer relationships or attract new customers of Tablo, timely collect amounts due, effectively manage our inventory levels, and have a material adverse effect on our bookings, revenues, results of operations, financial condition, and, ultimately, our future growth and profitability. In 2022, we launched a pilot clinical and administrative services program designed to help bridge our healthcare provider customers, particularly those challenged by staffing shortages, as they transition from using an outsourced inpatient dialysis provider to offering on-site inpatient dialysis services on their own. In return for a fair market value service fee, we assign members of our own employed nurses on a temporary basis to support participating providers to launch and manage an inpatient dialysis program using Tablo and, as full-time staff is hired, to help train and onboard those nurses. However, our pilot clinical and administrative services 18-month program may not be successful in achieving the objectives we intend and anticipate, may fail to meet our customers' expectations, may not generate sufficient returns to justify our investment, or may result in unanticipated costs, which could harm our reputation and customer relationships, and adversely impact our operating margins and results of operations. From a supply chain perspective, we have worked closely with our manufacturing partners and suppliers to enable us to source key components and maintain appropriate inventory levels to meet customer demand, and have not experienced material disruptions in our supply chain to date. However, macroeconomic factors such as rising inflation, increasing labor costs, and surges and shifts in consumer demand have disrupted the operations of certain of our third-party suppliers, resulting, in some cases, in increased lead times and higher component costs. We believe that localizing production of a majority of Tablo cartridges in Mexico (to our Mexico-based contract manufacturer and, more recently, in-house at our manufacturing facility) has helped achieve cost reductions through lower freight costs, further our long-term gross margin expansion and supply continuity strategies and improve the flexibility of our operations. However, we may face increased supply chain constraints in the future, which could negatively impact our ability to meet customer demand on a timely basis, result in customer dissatisfaction and adversely impact our operating margins and results of operations. Results of Operations The following table summarizes our results of operations for the three and six months ended June 30, 2024 and 2023 (in thousands):

Three Months Ended	Six Months Ended	June 30, 2024	June 30, 2023	2024	2023
Revenue:				\$ 19,238	\$ 29,330
Product revenue				\$ 39,666	\$ 57,109
Service and other revenue				\$ 8,150	\$ 6,710
				\$ 15,890	\$ 12,398
				\$ 27,388	\$ 36,040
Cost of revenue:				\$ 55,556	\$ 69,507
Cost of product revenue				\$ 10,567	\$ 22,212
Cost of service and other revenue				\$ 23,148	\$ 43,029
				\$ 7,039	\$ 6,125
				\$ 14,411	\$ 12,347
				\$ 17,606	\$ 28,337
				\$ 37,559	\$ 55,376
Gross profit				\$ 9,782	\$ 7,703
Operating expenses:				\$ 17,997	\$ 14,131
Research and development				\$ 9,734	\$ 14,906
Sales and marketing				\$ 22,369	\$ 28,699
General and administrative				\$ 12,684	\$ 11,290
Total operating expenses				\$ 40,546	\$ 51,181
Interest income and other income, net				\$ 85,673	\$ 85,963
Interest expense				\$ (6,010)	\$ (6,045)
Provision for income taxes				\$ (3,103)	\$ (11,978)
Loss before provision for income taxes				\$ (34,303)	\$ (43,913)
Net loss				\$ (74,085)	\$ (74,085)
Comparison of the Three and Six Months Ended June 30, 2024 and 2023 Revenue				\$ (44,046)	\$ (87,692)
Revenue:				\$ (74,398)	\$ (88,017)
Product revenue				\$ (17,443)	\$ (13,951)
Service and other revenue				\$ (31%)	\$ (20%)
Total revenue				\$ 27,388	\$ 36,040
Net loss				\$ (8,652)	\$ (8,652)
Change				\$ (24%)	\$ (24%)
(dollars in thousands)				\$ 55,556	\$ 55,556
Revenue:				\$ 69,507	\$ 69,507
Product revenue				\$ (13,951)	\$ (13,951)
Service and other revenue				\$ 28%	\$ 28%
Total revenue				\$ 27,388	\$ 27,388
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 36,040	\$ 36,040
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ (10,092)	\$ (10,092)
Service and other revenue				\$ (34%)	\$ (34%)
Total revenue				\$ 27,388	\$ 27,388
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 36,040	\$ 36,040
Revenue:				\$ 57,109	\$ 57,109
Product revenue				\$ 19,238	\$ 19,238
Service and other revenue				\$ 8,150	\$ 8,150
Total revenue				\$ 27,388	\$ 27,388
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 36,040	\$ 36,040
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,666
Net loss				\$ (325)	\$ (325)
Change				\$ (34%)	\$ (34%)
(dollars in thousands)				\$ 39,666	\$ 39,666
Revenue:				\$ 39,666	\$ 39,666
Product revenue				\$ 39,666	\$ 39,666
Service and other revenue				\$ 39,666	\$ 39,666
Total revenue				\$ 39,666	\$ 39,6

warranty liability. The net cash outflow from operating assets and liabilities was partially offset by an increase in deferred revenue due to growth in our business and a decrease in prepaid expenses and other assets. Investing Activities The net cash used in investing activities of \$20.1 million for the six months ended June 30, 2024 was due to the purchases of short-term investment securities of \$128.4 million and the purchases of property and equipment of \$0.5 million, which was partially offset by the maturities of short-term investment securities of \$108.8 million.

Financing Activities The net cash provided by financing activities of \$68.7 million for the six months ended June 30, 2024 was due to the net proceeds of \$66.5 million from borrowings under the SLR Term Loan Facility and the proceeds from employee exercises of stock options and ESPP purchases. 21 ¹ Critical Accounting Estimates Management's discussion and analysis of the financial condition and results of operations is based on the financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses incurred during the reporting periods. The estimates are based on historical experience and on various other factors that are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no new or significant changes in our critical accounting estimates as compared to the critical accounting estimates disclosed in Part II Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" of our 2023 Annual Report. Item 3. Quantitative and Qualitative Disclosures About Market Risk Our market risks related to interest rate and foreign currency exchange rates are described in Part II Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," of our 2023 Annual Report. Our exposure to market risks has not changed materially since December 31, 2023. Item 4. Controls and Procedures. Evaluation of Disclosure Controls and Procedures Our management, with the participation and supervision of our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (Exchange Act) as of the end of the period covered by this Quarterly Report. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to our management, including our Chief Executive Officer and the Chief Financial Officer, to allow timely decisions regarding required disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective at a reasonable assurance level as of the end of the period covered by this Quarterly Report. Changes in Internal Control over Financial Reporting There were no changes in our internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 22 ² PART II "OTHER INFORMATION" Item 1. Legal Proceedings. From time to time we may become involved in legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. We are not presently a party to any legal proceedings that, if determined adversely to us, would individually or taken together have a material adverse effect on our business, results of operations, financial condition or cash flows. Item 1A. Risk Factors. You should carefully consider the risk factors discussed in Part I, "Item 1A. Risk Factors" in our 2023 Annual Report, as updated by the risk factors discussed in Part II, "Item 1A. Risk Factors" in our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024 (Q1 2024 Quarterly Report), which could materially affect our business, financial position, or future results of operations. There have been no material changes to the risk factors described in our 2023 Annual Report, as updated by our Q1 2024 Quarterly Report, except as set forth below. The risks described in our 2023 Annual Report and Q1 2024 Quarterly Report, as updated below, are not the only risks that we face. Additional risks and uncertainties not precisely known to us, or that we currently deem to be immaterial, may also arise and materially impact our business. If any of these risks occur, our business, results of operations and financial condition could be materially and adversely affected and the trading price of our common stock could decline. If we fail to effectively retain our commercial team and optimize our sales processes, or fail to expand the adoption of Tablo as we focus more heavily on enterprise selling, we may not be able to generate revenue growth. ³ We have relatively limited experience marketing and selling Tablo. We currently rely on our direct sales force to sell Tablo in the United States, and any failure to maintain, leverage and optimize our direct sales force will negatively affect our business, financial condition and results of operations. The members of our direct sales force are highly trained and possess substantial technical expertise, which we believe is critical in increasing adoption of Tablo. The members of our U.S. sales force are at-will employees. The loss of these personnel to competitors, or otherwise, will negatively affect our business, financial condition and results of operations. If we are unable to retain our direct sales force personnel or replace them with individuals of equivalent technical expertise and qualifications, or if we are unable to successfully instill such technical expertise in replacement personnel, it may negatively affect our business, financial condition and results of operations. In addition, our services revenue is dependent in part on our FSEs, and any failure to maintain, or adequately train, our team of FSEs could negatively impact our services revenue. In order to generate future growth, we plan to leverage and optimize our sales and marketing infrastructure to increase the number of customers that adopt Tablo. In addition, identifying and recruiting qualified sales and marketing personnel and training them on Tablo, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It often takes several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing techniques or products that utilize independent third parties, which could place us at a competitive disadvantage. It will negatively affect our business, financial condition and results of operations if our efforts to optimize and train our sales force do not generate a corresponding increase in revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for Tablo. In addition, our ability to generate revenue growth depends on the success of our efforts to further evolve our commercial infrastructure and sales processes to support the growth of our business in the home and acute markets. Any failure to hire, optimize, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time or timely

reduce fixed costs, or to evolve and scale our commercial infrastructure and sales processes, could negatively affect our business, financial condition and results of operations. Our ability to increase our customer base and achieve broader market acceptance of Tablo will depend to a significant extent on the effectiveness of our marketing efforts. We plan to continue dedicating resources to our marketing programs, and it will negatively affect our business, financial condition and results of operations if our marketing efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of Tablo in a cost-effective manner is critical to achieving broad acceptance of Tablo. Promotion activities may not generate patient or physician awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur in building our brand. If we fail to successfully promote, maintain and protect our brand, we may fail to attract or retain the physician acceptance necessary to realize a sufficient return on our brand building efforts, or to achieve the level of brand awareness that is critical for broad adoption of Tablo. ²³ Moreover, we may periodically adjust our sales organization or sales strategies in response to market shifts or opportunities, changes in our current or prospective customers, competitive threats, management changes, sales headcount changes, product and service introductions or enhancements, sales performance, cost reduction initiatives, and other internal and external considerations. Any such changes may result in disruptions in our sales cycle or a reduction of productivity, which could negatively impact our ²³ revenue growth. For example, during the second quarter of 2024, we observed a further elongation of our sales cycle, which contributed to an adverse impact on our revenues for the quarter, and which we believe was due in part to our transition beyond earlier stage adoption of Tablo. We identified a need to evolve our sales strategy to focus more heavily on enterprise selling, which often requires approvals and commitment across a larger base of stakeholders within a health system including clinical, financial and operational executives, and can elongate the sales cycle. We determined that this shift requires additional training, skill-building and optimization of our sales team and sales processes. In connection with steps we are taking to help optimize our commercial organization, and to help improve operational efficiencies and reduce operating expenses to align with anticipated revenue growth, in the third quarter of 2024, we initiated a restructuring plan primarily impacting our commercial organization. These actions could result in short-term or long-term disruption of our sales cycle and may not produce the cost savings, efficiencies and other benefits we anticipate or desire. Our ability to achieve the anticipated cost savings, efficiencies and other benefits from these actions on the timeframe we expect, or at all, is subject to estimates and assumptions, which are subject to uncertainties. If our estimates and assumptions are incorrect, if we are unsuccessful at implementing these changes or if we otherwise encounter deficiencies or inefficiencies in our infrastructure or processes which we did not anticipate, it could harm our business, financial condition, results of operations and, ultimately, our future growth and profitability. In addition, these actions may heighten certain of the risks described above, in particular, our ability to attract and retain talented sales and marketing personnel may be adversely impacted, which could harm our business. The terms of our credit agreement require us to meet certain operating and financial covenants, place restrictions on our operating and financial flexibility and subject us to interest rate risk, and our ability to access additional borrowings is subject to us achieving certain net revenue milestones and obtaining lenders' credit approval. We entered into the SLR Credit Facilities on November 3, 2022, which provide for (i) up to \$250.0 million of term loans pursuant to the SLR Loan Agreement and (ii) up to a \$50.0 million asset-based revolving credit facility pursuant to the SLR Revolving Credit Agreement. We have already borrowed \$200.0 million of term loans, the full amount available under certain borrowing limitations that limit the maximum principal amount outstanding under the SLR Credit Facilities. In addition, additional borrowings under the SLR Credit Facilities are subject to us achieving certain net revenue milestones and/or obtaining lenders' credit approval. As a result, we cannot rely on further borrowings under the SLR Credit Facilities to fund our operations. In addition, principal amounts outstanding under each of the SLR Term Loan Facility and the SLR Revolver accrue interest at variable interest rates tied to SOFR. As a result, our borrowings under the facilities are subject to interest rate risk. An adverse change in interest rates for our borrowings would increase our borrowing costs which may restrict our access to capital in the future and, ultimately, could adversely affect our financial condition and results of operations. See the section titled "Management's Discussion and Analysis of Financial Condition and Results of Operations" Liquidity and Capital Resources" Debt Obligations" SLR Debt Financing. ²⁴ The SLR Credit Facility Agreements contain customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting (including the timely delivery of audited financial statements together with an unqualified report from our independent registered accountants thereon) and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property or to pay any dividends or other distributions on capital stock. Accordingly, the terms may restrict our current and future operations, particularly our ability to respond to certain changes in our business or industry or take future actions. In addition, the SLR Credit Facility Agreements also include a financial covenant that, beginning with the fiscal quarter ending December 31, 2023, requires us to either (i) maintain certain levels of cash and cash equivalents in accounts subject to control agreements in favor of Agent and ABL Lender of at least the sum of (a) 50% of the outstanding obligations under the SLR Term Loan Facility and (b) the amount of the Company's accounts payable that have not been paid within 120 days from the invoice date thereof or (ii) generate net product and product related revenue in excess of specified amounts and maintain gross profit margins in excess of specified percentages, in each case, for applicable measuring periods. If we fail to comply with any covenants, payments or other terms of either SLR Credit Facility Agreement, our agent or lender, as applicable, could declare an event of default, which would give it the right to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, our agent or lender, as applicable, would have the right to proceed against the assets we provided as collateral pursuant to the SLR Loan Agreement or SLR Revolving Credit Agreement, as applicable. If the debt under either SLR Credit Facility Agreement was accelerated, we may not have sufficient cash or be able to sell sufficient assets to repay this debt, which would harm our business and financial condition. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds. None. Item 3. Defaults Upon Senior Securities. None. ²⁴ Item 4. Mine Safety Disclosures. Not applicable. Item 5. Other Information. During the period covered by this report, none of the Company's directors or officers has adopted or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Exchange Act). ²⁵ Item 6. Exhibits. ²⁶ ²⁷ ²⁸ ²⁹ ³⁰ ³¹ ³² ³³ ³⁴ ³⁵ ³⁶ ³⁷ ³⁸ ³⁹ ⁴⁰ ⁴¹ ⁴² ⁴³ ⁴⁴ ⁴⁵ ⁴⁶ ⁴⁷ ⁴⁸ ⁴⁹ ⁵⁰ ⁵¹ ⁵² ⁵³ ⁵⁴ ⁵⁵ ⁵⁶ ⁵⁷ ⁵⁸ ⁵⁹ ⁶⁰ ⁶¹ ⁶² ⁶³ ⁶⁴ ⁶⁵ ⁶⁶ ⁶⁷ ⁶⁸ ⁶⁹ ⁷⁰ ⁷¹ ⁷² ⁷³ ⁷⁴ ⁷⁵ ⁷⁶ ⁷⁷ ⁷⁸ ⁷⁹ ⁸⁰ ⁸¹ ⁸² ⁸³ ⁸⁴ ⁸⁵ ⁸⁶ ⁸⁷ ⁸⁸ ⁸⁹ ⁹⁰ ⁹¹ ⁹² ⁹³ ⁹⁴ ⁹⁵ ⁹⁶ ⁹⁷ ⁹⁸ ⁹⁹ ¹⁰⁰ ¹⁰¹ ¹⁰² ¹⁰³ ¹⁰⁴ ¹⁰⁵ ¹⁰⁶ ¹⁰⁷ ¹⁰⁸ ¹⁰⁹ ¹¹⁰ ¹¹¹ ¹¹² ¹¹³ ¹¹⁴ ¹¹⁵ ¹¹⁶ ¹¹⁷ ¹¹⁸ ¹¹⁹ ¹²⁰ ¹²¹ ¹²² ¹²³ ¹²⁴ ¹²⁵ ¹²⁶ ¹²⁷ ¹²⁸ ¹²⁹ ¹³⁰ ¹³¹ ¹³² ¹³³ ¹³⁴ ¹³⁵ ¹³⁶ ¹³⁷ ¹³⁸ ¹³⁹ ¹⁴⁰ ¹⁴¹ ¹⁴² ¹⁴³ ¹⁴⁴ ¹⁴⁵ ¹⁴⁶ ¹⁴⁷ ¹⁴⁸ ¹⁴⁹ ¹⁵⁰ ¹⁵¹ ¹⁵² ¹⁵³ ¹⁵⁴ ¹⁵⁵ ¹⁵⁶ ¹⁵⁷ ¹⁵⁸ ¹⁵⁹ ¹⁶⁰ ¹⁶¹ ¹⁶² ¹⁶³ ¹⁶⁴ ¹⁶⁵ ¹⁶⁶ ¹⁶⁷ ¹⁶⁸ ¹⁶⁹ ¹⁷⁰ ¹⁷¹ ¹⁷² ¹⁷³ ¹⁷⁴ ¹⁷⁵ ¹⁷⁶ ¹⁷⁷ ¹⁷⁸ ¹⁷⁹ ¹⁸⁰ ¹⁸¹ ¹⁸² ¹⁸³ ¹⁸⁴ ¹⁸⁵ ¹⁸⁶ ¹⁸⁷ ¹⁸⁸ ¹⁸⁹ ¹⁹⁰ ¹⁹¹ ¹⁹² ¹⁹³ ¹⁹⁴ ¹⁹⁵ ¹⁹⁶ ¹⁹⁷ ¹⁹⁸ ¹⁹⁹ ²⁰⁰ ²⁰¹ ²⁰² ²⁰³ ²⁰⁴ ²⁰⁵ ²⁰⁶ ²⁰⁷ ²⁰⁸ ²⁰⁹ ²¹⁰ ²¹¹ ²¹² ²¹³ ²¹⁴ ²¹⁵ ²¹⁶ ²¹⁷ ²¹⁸ ²¹⁹ ²²⁰ ²²¹ ²²² ²²³ ²²⁴ ²²⁵ ²²⁶ ²²⁷ ²²⁸ ²²⁹ ²³⁰ ²³¹ ²³² ²³³ ²³⁴ ²³⁵ ²³⁶ ²³⁷ ²³⁸ ²³⁹ ²⁴⁰ ²⁴¹ ²⁴² ²⁴³ ²⁴⁴ ²⁴⁵ ²⁴⁶ ²⁴⁷ ²⁴⁸ ²⁴⁹ ²⁵⁰ ²⁵¹ ²⁵² ²⁵³ ²⁵⁴ ²⁵⁵ ²⁵⁶ ²⁵⁷ ²⁵⁸ ²⁵⁹ ²⁶⁰ ²⁶¹ ²⁶² ²⁶³ ²⁶⁴ ²⁶⁵ ²⁶⁶ ²⁶⁷ ²⁶⁸ ²⁶⁹ ²⁷⁰ ²⁷¹ ²⁷² ²⁷³ ²⁷⁴ ²⁷⁵ ²⁷⁶ ²⁷⁷ ²⁷⁸ ²⁷⁹ ²⁸⁰ ²⁸¹ ²⁸² ²⁸³ ²⁸⁴ ²⁸⁵ ²⁸⁶ ²⁸⁷ ²⁸⁸ ²⁸⁹ ²⁹⁰ ²⁹¹ ²⁹² ²⁹³ ²⁹⁴ ²⁹⁵ ²⁹⁶ ²⁹⁷ ²⁹⁸ ²⁹⁹ ³⁰⁰ ³⁰¹ ³⁰² ³⁰³ ³⁰⁴ ³⁰⁵ ³⁰⁶ ³⁰⁷ ³⁰⁸ ³⁰⁹ ³¹⁰ ³¹¹ ³¹² ³¹³ ³¹⁴ ³¹⁵ ³¹⁶ ³¹⁷ ³¹⁸ ³¹⁹ ³²⁰ ³²¹ ³²² ³²³ ³²⁴ ³²⁵ ³²⁶ ³²⁷ ³²⁸ ³²⁹ ³³⁰ ³³¹ ³³² ³³³ ³³⁴ ³³⁵ ³³⁶ ³³⁷ ³³⁸ ³³⁹ ³⁴⁰ ³⁴¹ ³⁴² ³⁴³ ³⁴⁴ ³⁴⁵ ³⁴⁶ ³⁴⁷ ³⁴⁸ ³⁴⁹ ³⁵⁰ ³⁵¹ ³⁵² ³⁵³ ³⁵⁴ ³⁵⁵ ³⁵⁶ ³⁵⁷ ³⁵⁸ ³⁵⁹ ³⁶⁰ ³⁶¹ ³⁶² ³⁶³ ³⁶⁴ ³⁶⁵ ³⁶⁶ ³⁶⁷ ³⁶⁸ ³⁶⁹ ³⁷⁰ ³⁷¹ ³⁷² ³⁷³ ³⁷⁴ ³⁷⁵ ³⁷⁶ ³⁷⁷ ³⁷⁸ ³⁷⁹ ³⁸⁰ ³⁸¹ ³⁸² ³⁸³ ³⁸⁴ ³⁸⁵ ³⁸⁶ ³⁸⁷ ³⁸⁸ ³⁸⁹ ³⁹⁰ ³⁹¹ ³⁹² ³⁹³ ³⁹⁴ ³⁹⁵ ³⁹⁶ ³⁹⁷ ³⁹⁸ ³⁹⁹ ⁴⁰⁰ ⁴⁰¹ ⁴⁰² ⁴⁰³ ⁴⁰⁴ ⁴⁰⁵ ⁴⁰⁶ ⁴⁰⁷ ⁴⁰⁸ ⁴⁰⁹ ⁴¹⁰ ⁴¹¹ ⁴¹² ⁴¹³ ⁴¹⁴ ⁴¹⁵ ⁴¹⁶ ⁴¹⁷ ⁴¹⁸ ⁴¹⁹ ⁴²⁰ ⁴²¹ ⁴²² ⁴²³ ⁴²⁴ ⁴²⁵ ⁴²⁶ ⁴²⁷ ⁴²⁸ ⁴²⁹ ⁴³⁰ ⁴³¹ ⁴³² ⁴³³ ⁴³⁴ ⁴³⁵ ⁴³⁶ ⁴³⁷ ⁴³⁸ ⁴³⁹ ⁴⁴⁰ ⁴⁴¹ ⁴⁴² ⁴⁴³ ⁴⁴⁴ ⁴⁴⁵ ⁴⁴⁶ ⁴⁴⁷ ⁴⁴⁸ ⁴⁴⁹ ⁴⁵⁰ ⁴⁵¹ ⁴⁵² ⁴⁵³ ⁴⁵⁴ ⁴⁵⁵ ⁴⁵⁶ ⁴⁵⁷ ⁴⁵⁸ ⁴⁵⁹ ⁴⁶⁰ ⁴⁶¹ ⁴⁶² ⁴⁶³ ⁴⁶⁴ ⁴⁶⁵ ⁴⁶⁶ ⁴⁶⁷ ⁴⁶⁸ ⁴⁶⁹ ⁴⁷⁰ ⁴⁷¹ ⁴⁷² ⁴⁷³ ⁴⁷⁴ ⁴⁷⁵ ⁴⁷⁶ ⁴⁷⁷ ⁴⁷⁸ ⁴⁷⁹ ⁴⁸⁰ ⁴⁸¹ ⁴⁸² ⁴⁸³ ⁴⁸⁴ ⁴⁸⁵ ⁴⁸⁶ ⁴⁸⁷ ⁴⁸⁸ ⁴⁸⁹ ⁴⁹⁰ ⁴⁹¹ ⁴⁹² ⁴⁹³ ⁴⁹⁴ ⁴⁹⁵ ⁴⁹⁶ ⁴⁹⁷ ⁴⁹⁸ ⁴⁹⁹ ⁵⁰⁰ ⁵⁰¹ ⁵⁰² ⁵⁰³ ⁵⁰⁴ ⁵⁰⁵ ⁵⁰⁶ ⁵⁰⁷ ⁵⁰⁸ ⁵⁰⁹ ⁵¹⁰ ⁵¹¹ ⁵¹² ⁵¹³ ⁵¹⁴ ⁵¹⁵ ⁵¹⁶ ⁵¹⁷ ⁵¹⁸ ⁵¹⁹ ⁵²⁰ ⁵²¹ ⁵²² ⁵²³ ⁵²⁴ ⁵²⁵ ⁵²⁶ ⁵²⁷ ⁵²⁸ ⁵²⁹ ⁵³⁰ ⁵³¹ ⁵³² ⁵³³ ⁵³⁴ ⁵³⁵ ⁵³⁶ ⁵³⁷ ⁵³⁸ ⁵³⁹ ⁵⁴⁰ ⁵⁴¹ ⁵⁴² ⁵⁴³ ⁵⁴⁴ ⁵⁴⁵ ⁵⁴⁶ ⁵⁴⁷ ⁵⁴⁸ ⁵⁴⁹ ⁵⁵⁰ ⁵⁵¹ ⁵⁵² ⁵⁵³ ⁵⁵⁴ ⁵⁵⁵ ⁵⁵⁶ ⁵⁵⁷ ⁵⁵⁸ ⁵⁵⁹ ⁵⁵⁰ ⁵⁵¹ ⁵⁵² ⁵⁵³ ⁵⁵⁴ ⁵⁵⁵ ⁵⁵⁶ ⁵⁵⁷ ⁵⁵⁸ ⁵⁵⁹ ⁵⁶⁰ ⁵⁶¹ ⁵⁶² ⁵⁶³ ⁵⁶⁴ ⁵⁶⁵ ⁵⁶⁶ ⁵⁶⁷ ⁵⁶⁸ ⁵⁶⁹ ⁵⁶⁰ ⁵⁶¹ ⁵⁶² ⁵⁶³ ⁵⁶⁴ ⁵⁶⁵ ⁵⁶⁶ ⁵⁶⁷ ⁵⁶⁸ ⁵⁶⁹ ⁵⁷⁰ ⁵⁷¹ ⁵⁷² ⁵⁷³ ⁵⁷⁴ ⁵⁷⁵ ⁵⁷⁶ ⁵⁷⁷ ⁵⁷⁸ ⁵⁷⁹ ⁵⁷⁰ ⁵⁷¹ ⁵⁷² ⁵⁷³ ⁵⁷⁴ ⁵⁷⁵ ⁵⁷⁶ ⁵⁷⁷ ⁵⁷⁸ ⁵⁷⁹ ⁵⁸⁰ ⁵⁸¹ ⁵⁸² ⁵⁸³ ⁵⁸⁴ ⁵⁸⁵ ⁵⁸⁶ ⁵⁸⁷ ⁵⁸⁸ ⁵⁸⁹ ⁵⁸⁰ ⁵⁸¹ ⁵⁸² ⁵⁸³ ⁵⁸⁴ ⁵⁸⁵ ⁵⁸⁶ ⁵⁸⁷ ⁵⁸⁸ ⁵⁸⁹ ⁵⁹⁰ ⁵⁹¹ ⁵⁹² ⁵⁹³ ⁵⁹⁴ ⁵⁹⁵ ⁵⁹⁶ ⁵⁹⁷ ⁵⁹⁸ ⁵⁹⁹ ⁵⁹⁰ ⁵⁹¹ ⁵⁹² ⁵⁹³ ⁵⁹⁴ ⁵⁹⁵ ⁵⁹⁶ ⁵⁹⁷ ⁵⁹⁸ ⁵⁹⁹ ⁶⁰⁰ ⁶⁰¹ ⁶⁰² ⁶⁰³ ⁶⁰⁴ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶⁰⁸ ⁶⁰⁹ ⁶⁰⁰ ⁶⁰¹ ⁶⁰² ⁶⁰³ ⁶⁰⁴ ⁶⁰⁵ ⁶⁰⁶ ⁶⁰⁷ ⁶⁰⁸ ⁶⁰⁹ ⁶¹⁰ ⁶¹¹ ⁶¹² ⁶¹³ ⁶¹⁴ ⁶¹⁵ ⁶¹⁶ ⁶¹⁷ ⁶¹⁸ ⁶¹⁹ ⁶¹⁰ ⁶¹¹ ⁶¹² ⁶¹³ ⁶¹⁴ ⁶¹⁵ ⁶¹⁶ ⁶¹⁷ ⁶¹⁸ ⁶¹⁹ ⁶²⁰ ⁶²¹ ⁶²² ⁶²³ ⁶²⁴ ⁶²⁵ ⁶²⁶ ⁶²⁷ ⁶²⁸ ⁶²⁹ ⁶²⁰ ⁶²¹ ⁶²² ⁶²³ ⁶²⁴ ⁶²⁵ ⁶²⁶ ⁶²⁷ ⁶²⁸ ⁶²⁹ ⁶³⁰ ⁶³¹ ⁶³² ⁶³³ ⁶³⁴ ⁶³⁵ ⁶³⁶ ⁶³⁷ ⁶³⁸ ⁶³⁹ ⁶³⁰ ⁶³¹ ⁶³² ⁶³³ ⁶³⁴ ⁶³⁵ ⁶³⁶ ⁶³⁷ ⁶³⁸ ⁶³⁹ ⁶⁴⁰ ⁶⁴¹ ⁶⁴² ⁶⁴³ ⁶⁴⁴ ⁶⁴⁵ ⁶⁴⁶ ⁶⁴⁷ ⁶⁴⁸ ⁶⁴⁹ ⁶⁴⁰ ⁶⁴¹ ⁶⁴² ⁶⁴³ ⁶⁴⁴ ⁶⁴⁵ ⁶⁴⁶ ⁶⁴⁷ ⁶⁴⁸ ⁶⁴⁹ ⁶⁵⁰ ⁶⁵¹ ⁶⁵² ⁶⁵³ ⁶⁵⁴ ⁶⁵⁵ ⁶⁵⁶ ⁶⁵⁷ ⁶⁵⁸ ⁶⁵⁹ ⁶⁵⁰ ⁶⁵¹ ⁶⁵² ⁶⁵³ ⁶⁵⁴ ⁶⁵⁵ ⁶⁵⁶ ⁶⁵⁷ ⁶⁵⁸ ⁶⁵⁹ ⁶⁶⁰ ⁶⁶¹ ⁶⁶² ⁶⁶³ ⁶⁶⁴ ⁶⁶⁵ ⁶⁶⁶ ⁶⁶⁷ ⁶⁶⁸ ⁶⁶⁹ ⁶⁶⁰ ⁶⁶¹ ⁶⁶² ⁶⁶³ ⁶⁶⁴ ⁶⁶⁵ ⁶⁶⁶ ⁶⁶⁷ ⁶⁶⁸ ⁶⁶⁹ ⁶⁷⁰ ⁶⁷¹ ⁶⁷² ⁶⁷³ ⁶⁷⁴ ⁶⁷⁵ ⁶⁷⁶ ⁶⁷⁷ ⁶⁷⁸ ⁶⁷⁹ ⁶⁷⁰ ⁶⁷¹ ⁶⁷² ⁶⁷³ ⁶⁷⁴ ⁶⁷⁵ ⁶⁷⁶ ⁶⁷⁷ ⁶⁷⁸ ⁶⁷⁹ ⁶⁸⁰ ⁶⁸¹ ⁶⁸² ⁶⁸³ ⁶⁸⁴ ⁶⁸⁵ ⁶⁸⁶ ⁶⁸⁷ ⁶⁸⁸ ⁶⁸⁹ ⁶⁸⁰ ⁶⁸¹ ⁶⁸² ⁶⁸³ ⁶⁸⁴ ⁶⁸⁵ ⁶⁸⁶ ⁶⁸⁷ ⁶⁸⁸ ⁶⁸⁹ ⁶⁹⁰ ⁶⁹¹ ⁶⁹² ⁶⁹³ ⁶⁹⁴ ⁶⁹⁵ ⁶⁹⁶ ⁶⁹⁷ ⁶⁹⁸ ⁶⁹⁹ ⁶⁹⁰ ⁶⁹¹ ⁶⁹² ⁶⁹³ ⁶⁹⁴ ⁶⁹⁵ ⁶⁹⁶ ⁶⁹⁷ ⁶⁹⁸ ⁶⁹⁹ ⁷⁰⁰ ⁷⁰¹ ⁷⁰² ⁷⁰³ ⁷⁰⁴ ⁷⁰⁵ ⁷⁰⁶ ⁷⁰⁷ ⁷⁰⁸ ⁷⁰⁹ ⁷⁰⁰ ⁷⁰¹ ⁷⁰² ⁷⁰³ ⁷⁰⁴ ⁷⁰⁵ ⁷⁰⁶ ⁷⁰⁷ ⁷⁰⁸ ⁷⁰⁹ ⁷¹⁰ ⁷¹¹ ⁷¹² ⁷¹³ ⁷¹⁴ ⁷¹⁵ ⁷¹⁶ ⁷¹⁷ ⁷¹⁸ ⁷¹⁹ ⁷¹⁰ ⁷¹¹ ⁷¹² ⁷¹³ ⁷¹⁴ ⁷¹⁵ ⁷¹⁶ ⁷¹⁷ ⁷¹⁸ ⁷¹⁹ ⁷²⁰ ⁷²¹ ⁷²² ⁷²³ ⁷²⁴ ⁷²⁵ ⁷²⁶ ⁷²⁷ ⁷²⁸ ⁷²⁹ ⁷²⁰ ⁷²¹ ⁷²² ⁷²³ ⁷²⁴ ⁷²⁵ ⁷²⁶ ⁷²⁷ ⁷²⁸ ⁷²⁹ ⁷³⁰ ⁷³¹ ⁷³² ⁷³³ ⁷³⁴ ⁷³⁵ ⁷³⁶ ⁷³⁷ ⁷³⁸ ⁷³⁹ ⁷³⁰ ⁷³¹ ⁷³² ⁷³³ ⁷³⁴ ⁷³⁵ ⁷³⁶ ⁷³⁷ ⁷³⁸ ⁷³⁹ ⁷⁴⁰ ⁷⁴¹ ⁷⁴² ⁷⁴³ ⁷⁴⁴ ⁷⁴⁵ ⁷⁴⁶ ⁷⁴⁷ ⁷⁴⁸ ⁷⁴⁹ ⁷⁴⁰ ⁷⁴¹ ⁷⁴² ⁷⁴³ ⁷⁴⁴ ⁷⁴⁵ ⁷⁴⁶ ⁷⁴⁷ ⁷⁴⁸ ⁷⁴⁹ ⁷⁵⁰ ⁷⁵¹ ⁷⁵² ⁷⁵³ ⁷⁵⁴ ⁷⁵⁵ ⁷⁵⁶ ⁷⁵⁷ ⁷⁵⁸ ⁷⁵⁹ ⁷⁵⁰ ⁷⁵¹ ⁷⁵² ⁷⁵³ ⁷⁵⁴ ⁷⁵⁵ ⁷⁵⁶ ⁷⁵⁷ ⁷⁵⁸ ⁷⁵⁹ ⁷⁶⁰ ⁷⁶¹ ⁷⁶² ⁷⁶³ ⁷⁶⁴ ⁷⁶⁵ ⁷⁶⁶ ⁷⁶⁷ ⁷⁶⁸ ⁷⁶⁹ ⁷⁶⁰ ⁷⁶¹ ⁷⁶² ⁷⁶³ ⁷⁶⁴ ⁷⁶⁵ ⁷⁶⁶ ⁷⁶⁷ ⁷⁶⁸ ⁷⁶⁹ ⁷⁷⁰ ⁷⁷¹ ⁷⁷² ⁷⁷³ ⁷⁷⁴ ⁷⁷⁵ ⁷⁷⁶ ⁷⁷⁷ ⁷⁷⁸ ⁷⁷⁹ ⁷⁷⁰ ⁷⁷¹ ⁷⁷² ⁷⁷³ ⁷⁷⁴ ⁷⁷⁵ ⁷⁷⁶ ⁷⁷⁷ ⁷⁷⁸ ⁷⁷⁹ ⁷⁸⁰ ⁷⁸¹ ⁷⁸² ⁷⁸³ ⁷⁸⁴ ⁷⁸⁵ ⁷⁸⁶ ⁷⁸⁷ ⁷⁸⁸ ⁷⁸⁹ ⁷⁸⁰ ⁷⁸¹ ⁷⁸² ⁷⁸³ ⁷⁸⁴ ⁷⁸⁵ ⁷⁸⁶ ⁷⁸⁷ ⁷⁸⁸ ⁷⁸⁹ ⁷⁹⁰ ⁷⁹¹ ⁷⁹² ⁷⁹³ ⁷⁹⁴ ⁷⁹⁵ ⁷⁹⁶ ⁷⁹⁷ ⁷⁹⁸ ⁷⁹⁹ ⁷⁹⁰ ⁷⁹¹ ⁷⁹² ⁷⁹³ ⁷⁹⁴ ⁷⁹⁵ ⁷⁹⁶ ⁷⁹⁷ ⁷⁹⁸ ⁷⁹⁹ ⁸⁰⁰ ⁸⁰¹ ⁸⁰² ⁸⁰³ ⁸⁰⁴ ⁸⁰⁵ ⁸⁰⁶ ⁸⁰⁷ ⁸⁰⁸ ⁸⁰⁹ ⁸⁰⁰ ⁸⁰¹ ⁸⁰² ⁸⁰³ ⁸⁰⁴ ⁸⁰⁵ ⁸⁰⁶ ⁸⁰⁷ ⁸⁰⁸ ⁸⁰⁹ ⁸¹⁰ ⁸¹¹ ⁸¹² ⁸¹³ ⁸¹⁴ ⁸¹⁵ ⁸¹⁶ ⁸¹⁷ ⁸¹⁸ ⁸¹⁹ ⁸¹⁰ ⁸¹¹ ⁸¹² ⁸¹³ ⁸¹⁴ ⁸¹⁵ ⁸¹⁶ ⁸¹⁷ ⁸¹⁸ ⁸¹⁹ ⁸²⁰ ⁸²¹ ⁸²² <

Restated Bylaws of Outset Medical, Inc. S-1/A 333-248225 3.2 September 9, 2020 A A A A A A A A A A A A A 4.1 A Form of Common Stock Certificate S-1/A 333-248225 4.1 September 9, 2020 A A A A A A A A A A A A A 4.2 A Amended and Restated Registration Rights Agreement S-1 333-248225 4.2 August 21, 2020 A A A A A A A A A A A A A 4.3 A Form of Series A Warrant Agreement #1 S-1 333-248225 4.3 August 21, 2020 A A A A A A A A A A A A A 4.4 A Form of Series A Warrant Agreement #2 S-1 333-248225 4.4 August 21, 2020 A A A A A A A A A A A A A 31.1* Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 A A A A A A A A A A A A A 31.2* Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) of the Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 A A A A A A A A A A A A A 32.1* Certification of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 A A A A A A A A A A A A A 101.INS* Inline XBRL Instance Document â€“ the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. A A A A A A A A A 101.SCH* A Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents A A A A A A A A A 104 A Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101) A A A A A A A * Filed herewith. 26 A SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized. A Outset Medical, Inc. Date: August 7, 2024 By: /s/ Leslie Trigg Leslie Trigg President and Chief Executive Officer(Principal Executive Officer) A Date: August 7, 2024 By: /s/ Nabeel Ahmed Nabeel Ahmed Chief Financial Officer(Principal Financial and Accounting Officer) A 27 EX-31.1 Exhibit 31.1 A CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Leslie Trigg, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Outset Medical, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): (a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and (b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. A Date: August 7, 2024 By: /s/ Leslie Trigg A A Leslie Trigg A A Chief Executive Officer(Principal Executive Officer) A A EX-31.2 Exhibit 31.2 A CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Nabeel Ahmed, certify that: 1.I have reviewed this Quarterly Report on Form 10-Q of Outset Medical, Inc.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; (c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d)disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent

functions): (a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ™s ability to record, process, summarize and report financial information; and (b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ™s internal control over financial reporting. Â Date: August 7, 2024 By: /s/ Nabeel Ahmed Â Nabeel Ahmed Â Chief Financial Officer(Principal Financial Officer) Â EX-32.1 Exhibit 32.1Â CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 Â In connection with the Quarterly Report of Outset Medical, Inc. (the âœCompanyâ€) on Form 10-Q for the period ending June 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the âœReportâ€), each of the undersigned certifies, pursuant to 18 U.S.C. Â§1350, as adopted pursuant to Â§906 of the Sarbanes-Oxley Act of 2002, that, to her/his knowledge: 1.The Report fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended; and 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations the Company. Â August 7, 2024 By: /s/ Leslie Trigg Â Leslie Trigg Â Chief Executive Officer Â (Principal Executive Officer) Â August 7, 2024 By: /s/ Nabeel Ahmed Â Nabeel Ahmed Â Chief Financial Officer Â (Principal Financial Officer) Â The foregoing certification is being furnished to the Securities and Exchange Commission as an exhibit to the Report and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and it is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Â Â